Title: LEGISLATIVE BILL 230
Official Title: LEGISLATIVE BILL 230
Number of Sections: 1
Source: versions - Final Reading
Media Type: application/pdf
Strikethrough Detection: 50 sections found

================================================================================

Section 1:
LB230 LB230
2025 2025
LEGISLATURE OF NEBRASKA
ONE HUNDRED NINTH LEGISLATURE
FIRST SESSION
FINAL READING
Introduced by Hallstrom, 1.
Read first time January 14, 2025
Committee: Judiciary
1 A BILL FOR AN ACT relating to public health and welfare; to amend
2 sections 28-405 and 77-5601, Revised Statutes Cumulative Supplement,
3 2024; to adopt the Kratom Consumer Protection Act; to regulate the
4 sale of nitrous oxide products; to provide penalties; to change
5 provisions of the schedules of controlled substances under the
6 Uniform Controlled Substances Act; to provide for the use of the
7 Department of Revenue Enforcement Fund for the Kratom Consumer
8 Protection Act; to provide operative dates; to repeal the original
9 sections; and to declare an emergency.
10 Be it enacted by the people of the State of Nebraska,
-1-
LB230 LB230
2025 2025
1 Section 1. Sections 1 to 15 of this act shall be known and may be
2 cited as the Kratom Consumer Protection Act.
3 Sec. 2. For purposes of the Kratom Consumer Protection Act:
4 (1) Attractive to children means products:
5 (a) Manufactured in the shape of humans, cartoons, or animals; or
6 (b) Manufactured in a form that bears any reasonable resemblance to
7 an existing candy product that is familiar to the public as a widely
8 distributed or a branded food product such that a product could be
9 mistaken for the branded food product, especially by children;
10 (2) Department means the Department of Revenue;
11 (3) Kratom means the plant mitragyna speciosa or any part of that
12 plant, including, but not limited to, all components present in the
13 natural plant;
14 (4) Kratom extract means the material obtained by extraction of
15 kratom leaves with a solvent consisting of water, ethanol, or food-grade
16 carbon dioxide, or any other solvent allowed by federal or state
17 regulation to be used in manufacturing a food ingredient;
18 (5) Kratom product means a food, ingredient, or dietary supplement
19 that:
20 (a) Consists of or contains kratom or kratom extract;
21 (b) Does not contain any synthesized kratom alkaloids, other
22 synthesized kratom constituents, or synthesized metabolites of any kratom
23 constituent;
24 (c) Does not contain a level of 7-hydroxymitragynine in the alkaloid
25 fraction that is greater than two percent of the alkaloid composition of
26 the kratom product; and
27 (d) Does not include any kratom product in any form that is
28 combustible, is intended to be used for vaporization, or is injectable;
29 (6) Processor means a person that manufacturers, packages, labels,
30 or distributes kratom products or advertises, represents, or holds itself
31 out as manufacturing, preparing, packaging, labeling, or distributing
-2-
LB230 LB230
2025 2025
1 kratom products;
2 (7) Retailer has the same meaning as in section 77-2701.32; and
3 (8) Synthesized means an alkaloid or alkaloid derivative that has
4 been created, in full or in part, by directed chemical, physical, or
5 biosynthetic conversion, including, but not limited to, fermentation,
6 recombinant techniques, yeast-derived, or enzymatic techniques, rather
7 than traditional food preparation techniques, such as heating or
8 extracting.
9 Sec. 3. (1) No person shall sell, offer for sale, provide, or
10 distribute a kratom product to a person under twenty-one years of age.
11 (2) An online retailer or marketplace that sells or offers for sale
12 a kratom product shall implement an age-verification system to ensure
13 compliance with this section.
14 Sec. 4. No person shall produce, manufacture, distribute, offer for
15 sale, sell, or introduce into commerce a kratom product in the State of
16 Nebraska if the product is manufactured in a manner that is attractive to
17 children.
18 Sec. 5. A kratom product sold, offered for sale, or introduced into
19 commerce in the State of Nebraska shall:
20 (1) Be manufactured, packaged, labeled, or held in a facility that
21 meets the requirements of 21 C.F.R. Part 111, as such regulations existed
22 on January 1, 2025; and
23 (2) Be manufactured, processed, packed, or held by a processor who
24 has registered with the federal Food and Drug Administration as a food
25 facility.
26 Sec. 6. A kratom product sold, offered for sale, or introduced into
27 commerce in the State of Nebraska shall have a label on each retail
28 package that clearly and conspicuously provides the following
29 information:
30 (1) The product is not recommended for use by individuals who are
31 under twenty-one years of age, who are pregnant, or who are
-3-
LB230 LB230
2025 2025
1 breastfeeding;
2 (2) A health care practitioner should be consulted prior to using
3 the product;
4 (3) The product may be habit-forming;
5 (4) The following statements: "These statements have not been
6 evaluated by the Food and Drug Administration. This product is not
7 intended to diagnose, treat, cure, or prevent any disease.";
8 (5) The name and place of business of the processor;
9 (6) Directions for use that include a recommended amount of the
10 kratom product per serving that is:
11 (a) Clearly described on the label for product forms such as
12 capsules, gummies, prepackaged, single-serving units, and similar product
13 forms; or
14 (b) A clear instruction or a mark on the package or container for
15 beverages or liquids;
16 (7) A recommended number of servings that can be safely consumed in
17 a twenty-four-hour period;
18 (8) A listing of the servings per container; and
19 (9) A listing of kratom alkaloids mitragynine and 7-
20 hydroxymitragynine and other ingredients in the product, including
21 quantitative declarations of the amount per serving of mitragynine.
22 Sec. 7. (1) The department shall establish, operate, and administer
23 a program to register kratom products. The Tax Commissioner shall
24 designate an implementation date for such program which date is on or
25 before January 1, 2026.
26 (2) Beginning on the implementation date designated by the Tax
27 Commissioner pursuant to subsection (1) of this section:
28 (a) No processor may manufacture, package, label, or distribute a
29 kratom product to be offered for sale in the State of Nebraska unless the
30 product has been registered with the department;
31 (b) Applications for product registration shall be submitted on a
-4-
LB230 LB230
2025 2025
1 form prescribed by the department. Each application shall include:
2 (i) The name, address, and state of organization for the processor
3 of the product;
4 (ii) A principal point of contact for the processor and contact
5 information for the point of contact;
6 (iii) The name of the product;
7 (iv) The product label;
8 (v) A certificate of analysis for the kratom product that states the
9 kratom product's alkaloid content and certifies that the kratom product
10 has a level of 7-hydroxymitragynine that is less than two percent of the
11 alkaloid composition of the kratom product from an independent
12 laboratory. Such laboratory shall obtain and maintain an International
13 Organization for Standardization and International Electrotechnical
14 Commission (ISO/IEC) 17025 accreditation for testing and calibration
15 laboratories from an accreditation body that is a signatory to the
16 International Laboratory Accreditation Cooperation Mutual Recognition
17 Arrangement;
18 (vi) A valid good manufacturing practice certificate issued by an
19 accredited third-party certification body in compliance with 21 C.F.R.
20 Part 111; and
21 (vii) A current food facility registration certificate issued by the
22 federal Food and Drug Administration for all facilities where kratom
23 products are manufactured, prepared, packaged, or labeled;
24 (c) A certificate of registration shall be valid for one calendar
25 year after the date of issue and shall not be transferable;
26 (d) The department may charge a fee for product registration
27 applications and may adjust such fee annually. The fee shall be
28 reasonable and shall not exceed any reasonable or necessary costs to
29 administer the Kratom Consumer Protection Act. The department shall remit
30 such fees to the State Treasurer for credit to the Department of Revenue
31 Enforcement Fund; and
-5-
LB230 LB230
2025 2025
1 (e) A product that contains the same kratom ingredients in the same
2 kratom delivery form, but is packaged, sold, or offered for sale in a
3 different container, package, or volume shall be included in a single
4 registration.
5 (3) If an application is incomplete or deficient, the department
6 shall, in a timely manner, notify the applicant in writing describing the
7 reason or reasons and request additional information. If such application
8 is not corrected or supplemented within thirty days after the
9 department's request, the department shall deny the application.
10 (4) If any false statement is made in any part of an application,
11 the department shall deny the application.
12 (5) A person aggrieved by the denial of an application may request a
13 hearing pursuant to section 11 of this act.
14 (6) A processor or retailer is not prohibited from selling,
15 preparing, manufacturing, distributing, maintaining, advertising,
16 representing, or holding itself out as selling, preparing, or maintaining
17 kratom products in the State of Nebraska prior to the implementation date
18 designated by the Tax Commissioner pursuant to subsection (1) of this
19 section, or while the first product registration applications submitted
20 by processors operating in the State of Nebraska as of January 1, 2025,
21 are pending approval or denial by the department.
22 Sec. 8. Beginning on the implementation date designated by the Tax
23 Commissioner pursuant to subsection (1) of section 7 of this act, the
24 department shall make public a list of all registered kratom products on
25 its website.
26 Sec. 9. (1) No person shall sell, offer for sale, provide, or
27 distribute an adulterated kratom product in the State of Nebraska.
28 (2) A product shall be deemed adulterated if:
29 (a) It contains any kratom alkaloid or metabolite, including 7-
30 hydroxymitragynine, and does not meet the definition of a kratom product
31 under section 2 of this act; or
-6-
LB230 LB230
2025 2025
1 (b) The kratom product is combined with a dangerous nonkratom
2 substance that contains a poisonous or otherwise deleterious nonkratom
3 ingredient, including, but not limited to, any substance listed as a
4 controlled substance under the laws of this state or federal law.
5 (3) Upon receipt of evidence that suggests a product may be an
6 adulterated kratom product, the department may require the person
7 selling, providing, or distributing the product to obtain an independent
8 third-party test of the product by a laboratory of the department's
9 choosing.
10 Sec. 10. (1) Any processor or retailer that violates any section of
11 the Kratom Consumer Protection Act, including those related to the
12 application or registration, or any of the rules and regulations adopted
13 and promulgated by the department that apply to processors or kratom
14 products shall be subject to the penalties provided in this section.
15 (2) For the first violation, the department shall impose a civil
16 penalty of up to one thousand dollars. For the second violation, the
17 department shall impose a civil penalty of up to five thousand dollars.
18 For a third violation and any subsequent violations, the department shall
19 impose a civil penalty of at least five thousand dollars and no more than
20 twenty thousand dollars and, if the violator is a processor, the
21 department shall prohibit the sale of any kratom products of such
22 processor within the State of Nebraska for a period of three years.
23 (3) For any processor or retailer that has no violation for a period
24 of four consecutive years, a new violation shall be treated as a first
25 violation.
26 (4) No determination that a violation has occurred shall be made
27 until notice has been given and a hearing has been held by the Tax
28 Commissioner as provided in section 11 of this act if requested by the
29 processor or retailer.
30 (5) A retailer shall not be found to be in violation of the Kratom
31 Consumer Protection Act if it is shown by a preponderance of the evidence
-7-
LB230 LB230
2025 2025
1 that the retailer relied in good faith upon the representation of a
2 processor that a product is not an adulterated kratom product as defined
3 in section 9 of this act or otherwise conformed to the act.
4 Sec. 11. (1) A processor or retailer aggrieved by a notice of
5 denial of an application issued under section 7 of this act or a notice
6 of violation issued under section 10 of this act may request a hearing.
7 (2) Such request shall be made within twenty days after the receipt
8 of any such notice.
9 (3) At such hearing the Tax Commissioner, or any officer or employee
10 of the Tax Commissioner designated in writing, may examine any books,
11 papers, memoranda, or other evidence bearing upon the matter at issue and
12 require the attendance of any officer or employee of the processor or
13 retailer or any person having knowledge pertinent to such hearing. The
14 Tax Commissioner or the Tax Commissioner's designee may administer oaths
15 to persons testifying at such hearing.
16 (4) During the hearing, the Tax Commissioner or the Tax
17 Commissioner's designee shall not be bound by the technical rules of
18 evidence, and no informality in any proceeding or in the manner of taking
19 testimony shall invalidate any order or decision made or approved by the
20 Tax Commissioner.
21 (5) Within a reasonable time after the hearing the Tax Commissioner
22 shall make a final decision or final determination and notify the
23 processor or retailer by mail of such decision or determination.
24 (6) If it is determined that a processor intentionally and
25 materially falsified any information contained in an application under
26 the Kratom Consumer Protection Act, the processor shall be ineligible to
27 obtain a certification of registration for a period of twelve months
28 after the date of such determination.
29 (7) A processor or retailer may appeal the decision of the Tax
30 Commissioner, and the appeal shall be in accordance with the
31 Administrative Procedure Act.
-8-
LB230 LB230
2025 2025
1 Sec. 12. The Attorney General shall have authority to enforce the
2 Kratom Consumer Protection Act pursuant to the Consumer Protection Act
3 and the Uniform Deceptive Trade Practices Act. This section shall not be
4 construed to allow for a private right of action under the Kratom
5 Consumer Protection Act even though such action is authorized under the
6 Consumer Protection Act and the Uniform Deceptive Trade Practices Act.
7 Sec. 13. (1) If a registered processor has been convicted by any
8 court of a violation of the Kratom Consumer Protection Act, the processor
9 may, in addition to the penalties for such offense, incur a forfeiture of
10 the certificate of registration for its kratom products and all money
11 that had been paid for such certificate of registration.
12 (2) If any materially false statement is made in any part of an
13 application submitted under section 7 of this act, the applicant shall be
14 subject to prosecution for perjury and if convicted may, in addition to
15 the penalties for such offense, incur a forfeiture of any certificate of
16 registration that was issued for the applicant's kratom products and all
17 money that had been paid for such certificate of registration.
18 Sec. 14. Except as otherwise provided in the Kratom Consumer
19 Protection Act, no political subdivision shall impose additional
20 restrictions on the manufacturing, packaging, labeling, distribution, or
21 sale of kratom products greater than or in addition to those enumerated
22 in the act.
23 Sec. 15. The department may adopt and promulgate rules and
24 regulations to carry out the Kratom Consumer Protection Act.
25 Sec. 16. (1) For purposes of this section:
26 (a) Delivery sale has the same meaning as in section 28-1418.01;
27 (b) Flavored nitrous oxide product means a nitrous oxide product:
28 (i) Having the taste or smell of any food, including, but not
29 limited to, any fruit, candy, dessert, alcoholic beverage, herb, or
30 spice, that is distinguishable by an ordinary consumer either prior to or
31 during consumption or use of the product;
-9-
LB230 LB230
2025 2025
1 (ii) That is marketed as having the taste or smell of any food,
2 including, but not limited to, any fruit, candy, dessert, alcoholic
3 beverage, herb, or spice; or
4 (iii) Regarding which the manufacturer, seller, or any person
5 authorized by, or acting with the consent of, the manufacturer or seller,
6 has made a public statement or claim, whether express or implied, that
7 such product has the taste or smell of any food, including, but not
8 limited to, any fruit, candy, dessert, alcoholic beverage, herb, or
9 spice; and
10 (c) Nitrous oxide product means a cartridge, cylinder, or tank
11 containing nitrous oxide.
12 (2) A business entity or corporation shall not sell, including by
13 delivery sale, offer for sale, give, furnish, or distribute to any
14 consumer in this state a nitrous oxide product or flavored nitrous oxide
15 product or willingly allow such products to be taken from such business
16 entity or corporation by any person. This subsection does not apply to a
17 nitrous oxide product, other than a flavored nitrous oxide product, that:
18 (a) Has been denatured or otherwise rendered unfit for human
19 consumption for use;
20 (b) Is intended for use by a manufacturer as part of a manufacturing
21 process or industrial operation;
22 (c) Is intended for use for automotive purposes;
23 (d) Is prescribed as part of the care or treatment of a disease,
24 condition, or injury by a licensed medical or dental practitioner; or
25 (e) Is a propellant in food or in food preparation for restaurant,
26 food service, or houseware products.
27 (3) A business entity or corporation that violates subsection (2) of
28 this section shall be subject to:
29 (a) A Class II misdemeanor for a first offense;
30 (b) A Class I misdemeanor for a second or subsequent offense; and
31 (c) A civil penalty of two thousand five hundred dollars for a first
-10-
LB230 LB230
2025 2025
1 or a subsequent offense.
2 (4) All nitrous oxide products or flavored nitrous oxide products
3 that are sold, offered for sale, given, or furnished in violation of this
4 section are subject to seizure, forfeiture, and destruction. The cost of
5 such seizure, forfeiture, and destruction shall be borne by the person
6 from whom the products are seized.
7 (5) Any common carrier that knowingly transports nitrous oxide
8 products or flavored nitrous oxide products for a business entity or
9 corporation that is in violation of subsection (2) of this section is
10 guilty of a Class II misdemeanor.
11 (6) In addition to any other penalty, a violation of this section
12 shall constitute a deceptive trade practice under the Uniform Deceptive
13 Trade Practices Act and shall be subject to any remedies or penalties
14 available for a violation of such act.
15 (7) This section does not apply to the following:
16 (a) The shipment of nitrous oxide products or flavored nitrous oxide
17 products to a foreign-trade zone that is established under 19 U.S.C. 81a
18 et seq., and that is located in this state if the products are from
19 outside of this country, were ordered by a distributor in another state,
20 and are not distributed in this state; or
21 (b) A government employee who is acting in the course of the
22 employee's official duties.
23 Sec. 17. Section 28-405, Revised Statutes Cumulative Supplement,
24 2024, is amended to read:
25 28-405 The following are the schedules of controlled substances
26 referred to in the Uniform Controlled Substances Act, unless specifically
27 contained on the list of exempted products of the Drug Enforcement
28 Administration of the United States Department of Justice as the list
29 existed on January 31, 2022:
30 Schedule I
31 (a) Any of the following opiates, including their isomers, esters,
-11-
LB230 LB230
2025 2025
1 ethers, salts, and salts of isomers, esters, and ethers, unless
2 specifically excepted, whenever the existence of such isomers, esters,
3 ethers, and salts is possible within the specific chemical designation:
4 (1) Acetylmethadol;
5 (2) Allylprodine;
6 (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also
7 known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
8 (4) Alphameprodine;
9 (5) Alphamethadol;
10 (6) Benzethidine;
11 (7) Betacetylmethadol;
12 (8) Betameprodine;
13 (9) Betamethadol;
14 (10) Betaprodine;
15 (11) Clonitazene;
16 (12) Dextromoramide;
17 (13) Difenoxin;
18 (14) Diampromide;
19 (15) Diethylthiambutene;
20 (16) Dimenoxadol;
21 (17) Dimepheptanol;
22 (18) Dimethylthiambutene;
23 (19) Dioxaphetyl butyrate;
24 (20) Dipipanone;
25 (21) Ethylmethylthiambutene;
26 (22) Etonitazene;
27 (23) Etoxeridine;
28 (24) Furethidine;
29 (25) Hydroxypethidine;
30 (26) Ketobemidone;
31 (27) Levomoramide;
-12-
LB230 LB230
2025 2025
1 (28) Levophenacylmorphan;
2 (29) Morpheridine;
3 (30) Noracymethadol;
4 (31) Norlevorphanol;
5 (32) Normethadone;
6 (33) Norpipanone;
7 (34) Phenadoxone;
8 (35) Phenampromide;
9 (36) Phenomorphan;
10 (37) Phenoperidine;
11 (38) Piritramide;
12 (39) Proheptazine;
13 (40) Properidine;
14 (41) Propiram;
15 (42) Racemoramide;
16 (43) Trimeperidine;
17 (44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-
18 piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
19 piperidine;
20 (45) Tilidine;
21 (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
22 phenylpropanamide, its optical and geometric isomers, salts, and salts of
23 isomers;
24 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical
25 isomers, salts, and salts of isomers;
26 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its
27 optical isomers, salts, and salts of isomers;
28 (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-
29 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of
30 isomers;
31 (50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-
-13-
LB230 LB230
2025 2025
1 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
2 of isomers;
3 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,
4 its optical isomers, salts, and salts of isomers;
5 (52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-
6 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
7 of isomers;
8 (53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-
9 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and
10 geometric isomers, salts, and salts of isomers;
11 (54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-
12 piperidinyl)-N-phenylpropanamide, its optical and geometric isomers,
13 salts, and salts of isomers;
14 (55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
15 (thenylfentanyl), its optical isomers, salts, and salts of isomers;
16 (56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-
17 propanamide, its optical isomers, salts, and salts of isomers;
18 (57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-
19 piperidinyl)propanamide, its optical isomers, salts, and salts of
20 isomers;
21 (58) U-47700, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
22 methylbenzamide;
23 (59) 4-Fluoroisobutyryl Fentanyl;
24 (60) Acetyl Fentanyl;
25 (61) Acyrloylfentanyl;
26 (62) AH-7921; 3, 4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]
27 benzamide;
28 (63) Butyryl fentanyl;
29 (64) Cyclopentyl fentanyl;
30 (65) Cyclopropyl fentanyl;
31 (66) Furanyl fentanyl;
-14-
LB230 LB230
2025 2025
1 (67) Isobutyryl fentanyl;
2 (68) Isotonitazene;
3 (69) Methoxyacetyl fentanyl;
4 (70) MT-45; 1-cyclohexyl-4-(1,2-diphenylethyl) piperazine;
5 (71) Tetrahydrofuranyl fentanyl;
6 (72) 2-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-
7 yl) propionamide;
8 (73) Ocfentanil;
9 (74) Ortho-Fluorofentanyl;
10 (75) Para-chloroisobutyryl fentanyl;
11 (76) Para-Fluorobutyryl Fentanyl;
12 (77) Valeryl fentanyl;
13 (78) Phenyl Fentanyl;
14 (79) Para-Methylfentanyl;
15 (80) Thiofuranyl Fentanyl;
16 (81) Beta-methyl Fentanyl;
17 (82) Beta'-Phenyl Fentanyl;
18 (83) Crotonyl Fentanyl;
19 (84) 2'-Fluoro Ortho-Fluorofentanyl;
20 (85) 4'-Methyl Acetyl Fentanyl;
21 (86) Ortho-Fluorobutyryl Fentanyl;
22 (87) Ortho-Methyl Acetylfentanyl;
23 (88) Ortho-Methyl Methoxyacetyl Fentanyl;
24 (89) Ortho-Fluoroacryl Fentanyl;
25 (90) Fentanyl Carbamate;
26 (91) Ortho-Fluoroisobutyryl Fentanyl;
27 (92) Para-Fluoro Furanyl Fentanyl;
28 (93) Para-Methoxybutyryl Fentanyl;
29 (94) Brorphine (other name: 1-(1-(1-(4-bromophenyl) ethyl)
30 piperidin-4-yl-1,3-dihydro-2H-benzo[D]imidazole-2-one); and
31 (95) Fentanyl-related substances, their isomers, esters, ethers,
-15-
LB230 LB230
2025 2025
1 salts and salts of isomers, esters, and ethers. Unless specifically
2 excepted, listed in another schedule, or specifically named in this
3 schedule, this includes any substance that is structurally related to
4 fentanyl by one or more of the following modifications:
5 (A) Replacement of the phenyl portion of the phenethyl group by any
6 monocycle, whether or not further substituted in or on the monocycle;
7 (B) Substitution in or on the phenethyl group with alkyl, alkenyl,
8 alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;
9 (C) Substitution in or on the piperidine ring with alkyl, alkenyl,
10 alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups;
11 (D) Replacement of the aniline ring with any aromatic monocycle
12 whether or not further substituted in or on the aromatic monocycle; or
13 (E) Replacement of the N-propionyl group by another acyl group.
14 (b) Any of the following opium derivatives, their salts, isomers,
15 and salts of isomers, unless specifically excepted, whenever the
16 existence of such salts, isomers, and salts of isomers is possible within
17 the specific chemical designation:
18 (1) Acetorphine;
19 (2) Acetyldihydrocodeine;
20 (3) Benzylmorphine;
21 (4) Codeine methylbromide;
22 (5) Codeine-N-Oxide;
23 (6) Cyprenorphine;
24 (7) Desomorphine;
25 (8) Dihydromorphine;
26 (9) Drotebanol;
27 (10) Etorphine, except hydrochloride salt;
28 (11) Heroin;
29 (12) Hydromorphinol;
30 (13) Methyldesorphine;
31 (14) Methyldihydromorphine;
-16-
LB230 LB230
2025 2025
1 (15) Morphine methylbromide;
2 (16) Morphine methylsulfonate;
3 (17) Morphine-N-Oxide;
4 (18) Myrophine;
5 (19) Nicocodeine;
6 (20) Nicomorphine;
7 (21) Normorphine;
8 (22) Pholcodine; and
9 (23) Thebacon.
10 (c) Any material, compound, mixture, or preparation which contains
11 any quantity of the following hallucinogenic substances, their salts,
12 isomers, and salts of isomers, unless specifically excepted, whenever the
13 existence of such salts, isomers, and salts of isomers is possible within
14 the specific chemical designation, and, for purposes of this subdivision
15 only, isomer shall include the optical, position, and geometric isomers:
16 (1) Bufotenine. Trade and other names shall include, but are not
17 limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-
18 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-
19 dimethyltryptamine; and mappine;
20 (2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall
21 include, but are not limited to: 4-bromo-2,5-dimethoxy-alpha-
22 methylphenethylamine; and 4-bromo-2,5-DMA;
23 (3) 4-methoxyamphetamine. Trade and other names shall include, but
24 are not limited to: 4-methoxy-alpha-methylphenethylamine; and
25 paramethoxyamphetamine, PMA;
26 (4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall
27 include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-
28 methylphenethylamine; DOM; and STP;
29 (5) Para-methoxymethamphetamine. Trade and other names shall
30 include, but are not limited to: 1-(4-Methoxyphenyl)-N-methylpropan-2-
31 amine, PMMA, and 4-MMA;
-17-
LB230 LB230
2025 2025
1 (6) Ibogaine. Trade and other names shall include, but are not
2 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-
3 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe
4 iboga;
5 (7) Lysergic acid diethylamide;
6 (8) Marijuana;
7 (9) Mescaline;
8 (10) Methoxetamine (MXE);
9 (11) Peyote. Peyote shall mean all parts of the plant presently
10 classified botanically as Lophophora williamsii Lemaire, whether growing
11 or not, the seeds thereof, any extract from any part of such plant, and
12 every compound, manufacture, salts, derivative, mixture, or preparation
13 of such plant or its seeds or extracts;
14 (12) Psilocybin;
15 (13) Psilocyn;
16 (14) Tetrahydrocannabinols, including, but not limited to, synthetic
17 equivalents of the substances contained in the plant or in the resinous
18 extractives of cannabis, sp. or synthetic substances, derivatives, and
19 their isomers with similar chemical structure and pharmacological
20 activity such as the following: Delta 1 cis or trans tetrahydrocannabinol
21 and their optical isomers, excluding dronabinol in a drug product
22 approved by the federal Food and Drug Administration; Delta 6 cis or
23 trans tetrahydrocannabinol and their optical isomers; and Delta 3,4 cis
24 or trans tetrahydrocannabinol and its optical isomers. Since nomenclature
25 of these substances is not internationally standardized, compounds of
26 these structures shall be included regardless of the numerical
27 designation of atomic positions covered. Tetrahydrocannabinols does not
28 include cannabidiol contained in a drug product approved by the federal
29 Food and Drug Administration;
30 (15) N-ethyl-3-piperidyl benzilate;
31 (16) N-methyl-3-piperidyl benzilate;
-18-
LB230 LB230
2025 2025
1 (17) Thiophene analog of phencyclidine. Trade and other names shall
2 include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine;
3 2-thienyl analog of phencyclidine; TPCP; and TCP;
4 (18) Hashish or concentrated cannabis;
5 (19) Parahexyl. Trade and other names shall include, but are not
6 limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
7 dibenzo(b,d)pyran; and Synhexyl;
8 (20) Ethylamine analog of phencyclidine. Trade and other names shall
9 include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; (1-
10 phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;
11 cyclohexamine; and PCE;
12 (21) Pyrrolidine analog of phencyclidine. Trade and other names
13 shall include, but are not limited to: 1-(1-phenylcyclohexyl)-
14 pyrrolidine; PCPy; and PHP;
15 (22) Alpha-ethyltryptamine. Some trade or other names: etryptamine;
16 Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;
17 alpha-ET; and AET;
18 (23) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;
19 (24) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;
20 (25) Alpha-methyltryptamine, which is also known as AMT;
21 (26) Salvia divinorum or Salvinorin A. Salvia divinorum or
22 Salvinorin A includes all parts of the plant presently classified
23 botanically as Salvia divinorum, whether growing or not, the seeds
24 thereof, any extract from any part of such plant, and every compound,
25 manufacture, derivative, mixture, or preparation of such plant, its
26 seeds, or its extracts, including salts, isomers, and salts of isomers
27 whenever the existence of such salts, isomers, and salts of isomers is
28 possible within the specific chemical designation;
29 (27) Any material, compound, mixture, or preparation containing any
30 quantity of synthetically produced cannabinoids as listed in subdivisions
31 (A) through (L) of this subdivision, including their salts, isomers,
-19-
LB230 LB230
2025 2025
1 salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic analogs,
2 unless specifically excepted elsewhere in this section. Since
3 nomenclature of these synthetically produced cannabinoids is not
4 internationally standardized and may continually evolve, these structures
5 or compounds of these structures shall be included under this
6 subdivision, regardless of their specific numerical designation of atomic
7 positions covered, so long as it can be determined through a recognized
8 method of scientific testing or analysis that the substance contains
9 properties that fit within one or more of the following categories:
10 (A) Tetrahydrocannabinols: Meaning tetrahydrocannabinols naturally
11 contained in a plant of the genus cannabis (cannabis plant), as well as
12 synthetic equivalents of the substances contained in the plant, or in the
13 resinous extractives of cannabis, sp. and/or synthetic substances,
14 derivatives, and their isomers with similar chemical structure and
15 pharmacological activity such as the following: Delta 1 cis or trans
16 tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans
17 tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans
18 tetrahydrocannabinol, and its optical isomers. This subdivision does not
19 include cannabidiol contained in a drug product approved by the federal
20 Food and Drug Administration;
21 (B) Naphthoylindoles: Any compound containing a 3-(1-
22 naphthoyl)indole structure with substitution at the nitrogen atom of the
23 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
24 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
25 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
26 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
27 tetrahydropyranylmethyl group, whether or not further substituted in or
28 on any of the listed ring systems to any extent;
29 (C) Naphthylmethylindoles: Any compound containing a 1 H-indol-3-
30 yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
31 of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
-20-
LB230 LB230
2025 2025
1 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
2 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
3 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
4 tetrahydropyranylmethyl group, whether or not further substituted in or
5 on any of the listed ring systems to any extent;
6 (D) Naphthoylpyrroles: Any compound containing a 3-(1-
7 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
8 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
9 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
10 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
11 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
12 tetrahydropyranylmethyl group, whether or not further substituted in or
13 on any of the listed ring systems to any extent;
14 (E) Naphthylideneindenes: Any compound containing a
15 naphthylideneindene structure with substitution at the 3-position of the
16 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
17 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
18 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
19 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
20 tetrahydropyranylmethyl group, whether or not further substituted in or
21 on any of the listed ring systems to any extent;
22 (F) Phenylacetylindoles: Any compound containing a 3-
23 phenylacetylindole structure with substitution at the nitrogen atom of
24 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
25 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
26 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
27 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
28 tetrahydropyranylmethyl group, whether or not further substituted in or
29 on any of the listed ring systems to any extent;
30 (G) Cyclohexylphenols: Any compound containing a 2-(3-
31 hydroxycyclohexyl)phenol structure with substitution at the 5-position of
-21-
LB230 LB230
2025 2025
1 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
2 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
3 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
4 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
5 tetrahydropyranylmethyl group, whether or not substituted in or on any of
6 the listed ring systems to any extent;
7 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole
8 structure with substitution at the nitrogen atom of the indole ring by an
9 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
10 cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-
11 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
12 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
13 further substituted in or on any of the listed ring systems to any
14 extent;
15 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole
16 structure with substitution at the nitrogen atom of the indole ring by an
17 alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl,
18 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
19 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
20 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
21 further substituted in or on any of the listed ring systems to any
22 extent;
23 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-
24 tetramethylcyclopropanoylindole structure with substitution at the
25 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
26 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
27 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
28 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
29 tetrahydropyranylmethyl group, whether or not further substituted in or
30 on any of the listed ring systems to any extent;
31 (K) Indole carboxamides: Any compound containing a 1-indole-3-
-22-
LB230 LB230
2025 2025
1 carboxamide structure with substitution at the nitrogen atom of the
2 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
3 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
4 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
5 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
6 tetrahydropyranylmethyl group, substitution at the carboxamide group by
7 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
8 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
9 substituted in or on any of the listed ring systems to any extent or to
10 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
11 propionaldehyde groups to any extent;
12 (L) Indole carboxylates: Any compound containing a 1-indole-3-
13 carboxylate structure with substitution at the nitrogen atom of the
14 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
15 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
16 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
17 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
18 tetrahydropyranylmethyl group, substitution at the carboxylate group by
19 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
20 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
21 substituted in or on any of the listed ring systems to any extent or to
22 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
23 propionaldehyde groups to any extent; and
24 (M) Any nonnaturally occurring substance, chemical compound,
25 mixture, or preparation, not specifically listed elsewhere in these
26 schedules and which is not approved for human consumption by the federal
27 Food and Drug Administration, containing or constituting a cannabinoid
28 receptor agonist as defined in section 28-401;
29 (28) Zipeprol 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-
30 yl]-1-phenylpropan-2-ol, including its isomers, esters, ethers, salts,
31 and salts of isomers, esters, and ethers, whenever the existence of such
-23-
LB230 LB230
2025 2025
1 isomers, esters, ethers, and salts is possible within the specific
2 chemical designation;
3 (29) Any material, compound, mixture, or preparation containing any
4 quantity of a substituted phenethylamine as listed in subdivisions (A)
5 through (C) of this subdivision, unless specifically excepted, listed in
6 another schedule, or specifically named in this schedule, that is
7 structurally derived from phenylethan-2-amine by substitution on the
8 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a
9 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by
10 substitution with one alkoxy and either one fused furan, tetrahydrofuran,
11 or tetrahydropyran ring system; or by substitution with two fused ring
12 systems from any combination of the furan, tetrahydrofuran, or
13 tetrahydropyran ring systems, whether or not the compound is further
14 modified in any of the following ways:
15 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,
16 trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-
17 position by any alkyl groups; or (C) substitution at the 2-amino nitrogen
18 atom with alkyl, dialkyl, benzyl, hydroxybenzyl, or methoxybenzyl groups,
19 and including, but not limited to:
20 (i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known
21 as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;
22 (ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known
23 as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;
24 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known
25 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;
26 (iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H
27 or 2,5-Dimethoxyphenethylamine;
28 (v) 2-(4-lodo-2,5-dimethoxyphenyl)ethanamine, which is also known as
29 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;
30 (vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known
31 as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;
-24-
LB230 LB230
2025 2025
1 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also
2 known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;
3 (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is
4 also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;
5 (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is
6 also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;
7 (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known
8 as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine;
9 (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also
10 known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;
11 (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also
12 known as DOI or 2,5-Dimethoxy-4-iodoamphetamine;
13 (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also
14 known as DOB or 2,5-Dimethoxy-4-bromoamphetamine;
15 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also
16 known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
17 (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
18 methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-
19 NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
20 (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-
21 methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-
22 NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
23 (xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,
24 which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-
25 methoxybenzyl)phenethylamine;
26 (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
27 methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or
28 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
29 (xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,
30 which is also known as 2CB-5-hemiFLY;
31 (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-
-25-
LB230 LB230
2025 2025
1 yl)ethanamine, which is also known as 2C-B-FLY;
2 (xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-
3 yl)ethanamine, which is also known as 2C-B-butterFLY;
4 (xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-
5 b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-
6 NBOMe;
7 (xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,
8 which is also known as bromo-benzodifuranylisopropylamine or bromo-
9 dragonFLY;
10 (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which
11 is also known as 2C-INBOH or 25I-NBOH;
12 (xxv) 5-(2-Aminopropyl)benzofuran, which is also known as 5-APB;
13 (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;
14 (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known
15 as 5-APDB;
16 (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also
17 known as 6-APDB;
18 (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-
19 dimethoxy-a-methylphenethylamine; 2, 5-DMA;
20 (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;
21 (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also
22 known as 2C-T-7;
23 (xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;
24 (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as
25 4-methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP;
26 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;
27 (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as
28 MDMA;
29 (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known
30 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;
31 (xxxvii) 3,4,5-trimethoxy amphetamine; and
-26-
LB230 LB230
2025 2025
1 (xxxviii) n-hydroxy-3, 4-Methylenedioxy-N-Hydroxyamphetamine, which
2 is also known as N-hydroxyMDA;
3 (30) Any material, compound, mixture, or preparation containing any
4 quantity of a substituted tryptamine unless specifically excepted, listed
5 in another schedule, or specifically named in this schedule, that is
6 structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also
7 known as tryptamine, by mono- or di-substitution of the amine nitrogen
8 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom
9 in a cyclic structure whether or not the compound is further substituted
10 at the alpha position with an alkyl group or whether or not further
11 substituted on the indole ring to any extent with any alkyl, alkoxy,
12 halo, hydroxyl, or acetoxy groups, and including, but not limited to:
13 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-
14 DALT;
15 (B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-
16 DMT or OAcetylpsilocin;
17 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-
18 HO-MET;
19 (D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-
20 HO-DIPT;
21 (E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as
22 5-MeOMiPT;
23 (F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-
24 DMT;
25 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-
26 MeO-DiPT;
27 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,
28 DET; and
29 (I) Dimethyltryptamine, which is also known as DMT; and
30 (31)(A) Any substance containing any quantity of the following
31 materials, compounds, mixtures, or structures:
-27-
LB230 LB230
2025 2025
1 (i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methylone;
2 (ii) 3,4-methylenedioxypyrovalerone, or MDPV;
3 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;
4 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;
5 (v) Fluoromethcathinone, or FMC;
6 (vi) Naphthylpyrovalerone, or naphyrone; or
7 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or
8 butylone; or
9 (B) Unless listed in another schedule, any substance which contains
10 any quantity of any material, compound, mixture, or structure, other than
11 bupropion, that is structurally derived by any means from 2-
12 aminopropan-1-one by substitution at the 1-position with either phenyl,
13 naphthyl, or thiophene ring systems, whether or not the compound is
14 further modified in any of the following ways:
15 (i) Substitution in the ring system to any extent with alkyl,
16 alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents,
17 whether or not further substituted in the ring system by one or more
18 other univalent substituents;
19 (ii) Substitution at the 3-position with an acyclic alkyl
20 substituent; or
21 (iii) Substitution at the 2-amino nitrogen atom with alkyl or
22 dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic
23 structure.
24 (d) Unless specifically excepted or unless listed in another
25 schedule, any material, compound, mixture, or preparation which contains
26 any quantity of the following substances having a depressant effect on
27 the central nervous system, including its salts, isomers, and salts of
28 isomers whenever the existence of such salts, isomers, and salts of
29 isomers is possible within the specific chemical designation:
30 (1) Amineptine 7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-
31 yl)amino]heptanoic acid, including its salts, isomers, and salts of
-28-
LB230 LB230
2025 2025
1 isomers;
2 (2) Mecloqualone;
3 (3) Methaqualone; and
4 (4) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-
5 hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium
6 Oxybate; and Sodium Oxybutyrate.
7 (e) Unless specifically excepted or unless listed in another
8 schedule, any material, compound, mixture, or preparation which contains
9 any quantity of the following substances having a stimulant effect on the
10 central nervous system, including its salts, isomers, and salts of
11 isomers:
12 (1) Fenethylline;
13 (2) N-ethylamphetamine;
14 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-
15 dihydro-5-phenyl-2-oxazolamine;
16 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-
17 aminopropiophenone; 2-aminopropiophenone; and norephedrone;
18 (5) Methcathinone, its salts, optical isomers, and salts of optical
19 isomers. Some other names: 2-(methylamino)-propiophenone; alpha-
20 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-
21 N-methylaminopropiophenone; methylcathinone; monomethylpropion;
22 ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; UR1432; and 4-MEC;
23 (6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-
24 phenyl-2-oxazolamine;
25 (7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;
26 and N,N-alpha-trimethylphenethylamine;
27 (8) Benzylpiperazine, 1-benzylpiperazine;
28 (9) 4,4'-dimethylaminorex (other names: 4,4'-DMAR, 4,5-dihydro-4-
29 methyl-5-(4-methylphenyl)-2-oxazolamine); and
30 (10) N-phenyl-N' -(3-(1- phenylpropan-2-yl)-1,2,3-oxadiazol-3-
31 ium-5-yl)carbamimidate), including its salts, isomers, and salts of
-29-
LB230 LB230
2025 2025
1 isomers.
2 (f) Any controlled substance analogue to the extent intended for
3 human consumption.
4 Schedule II
5 (a) Any of the following substances except those narcotic drugs
6 listed in other schedules whether produced directly or indirectly by
7 extraction from substances of vegetable origin, independently by means of
8 chemical synthesis, or by combination of extraction and chemical
9 synthesis:
10 (1) Opium and opiate, and any salt, compound, derivative, or
11 preparation of opium or opiate, excluding apomorphine, buprenorphine,
12 thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene,
13 naloxone, and naltrexone and their salts, but including the following:
14 (A) Raw opium;
15 (B) Opium extracts;
16 (C) Opium fluid;
17 (D) Powdered opium;
18 (E) Granulated opium;
19 (F) Tincture of opium;
20 (G) Codeine;
21 (H) Ethylmorphine;
22 (I) Etorphine hydrochloride;
23 (J) Hydrocodone;
24 (K) Hydromorphone;
25 (L) Metopon;
26 (M) Morphine;
27 (N) Oxycodone;
28 (O) Oxymorphone;
29 (P) Oripavine;
30 (Q) Thebaine; and
31 (R) Dihydroetorphine;
-30-
LB230 LB230
2025 2025
1 (2) Any salt, compound, derivative, or preparation thereof which is
2 chemically equivalent to or identical with any of the substances referred
3 to in subdivision (1) of this subdivision, except that these substances
4 shall not include the isoquinoline alkaloids of opium;
5 (3) Opium poppy and poppy straw;
6 (4) Coca leaves and any salt, compound, derivative, or preparation
7 of coca leaves, and any salt, compound, derivative, or preparation
8 thereof which is chemically equivalent to or identical with any of these
9 substances, including cocaine or ecgonine and its salts, optical isomers,
10 and salts of optical isomers, except that the substances shall not
11 include decocainized coca leaves or extractions which do not contain
12 cocaine or ecgonine; and
13 (5) Concentrate of poppy straw, the crude extract of poppy straw in
14 either liquid, solid, or powder form which contains the phenanthrene
15 alkaloids of the opium poppy.
16 (b) Unless specifically excepted or unless in another schedule any
17 of the following opiates, including their isomers, esters, ethers, salts,
18 and salts of their isomers, esters, and ethers whenever the existence of
19 such isomers, esters, ethers, and salts is possible within the specific
20 chemical designation, dextrorphan excepted:
21 (1) Alphaprodine;
22 (2) Anileridine;
23 (3) Bezitramide;
24 (4) Diphenoxylate;
25 (5) Fentanyl;
26 (6) Isomethadone;
27 (7) Levomethorphan;
28 (8) Levorphanol;
29 (9) Metazocine;
30 (10) Methadone;
31 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl
-31-
LB230 LB230
2025 2025
1 butane;
2 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-
3 diphenylpropane-carboxylic acid;
4 (13) Norfentanyl (N-phenyl-N-piperidin-4-yl) propionamide;
5 (14) Oliceridine;
6 (15) Pethidine or meperidine;
7 (16) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
8 (17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
9 carboxylate;
10 (18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-
11 carboxylic acid;
12 (19) Phenazocine;
13 (20) Piminodine;
14 (21) Racemethorphan;
15 (22) Racemorphan;
16 (23) Dihydrocodeine;
17 (24) Bulk Propoxyphene in nondosage forms;
18 (25) Sufentanil;
19 (26) Alfentanil;
20 (27) Levo-alphacetylmethadol which is also known as levo-alpha-
21 acetylmethadol, levomethadyl acetate, and LAAM;
22 (28) Carfentanil;
23 (29) Remifentanil;
24 (30) Tapentadol; and
25 (31) Thiafentanil.
26 (c) Any material, compound, mixture, or preparation which contains
27 any quantity of the following substances having a potential for abuse
28 associated with a stimulant effect on the central nervous system:
29 (1) Amphetamine, its salts, optical isomers, and salts of its
30 optical isomers;
31 (2) Phenmetrazine and its salts;
-32-
LB230 LB230
2025 2025
1 (3) Methamphetamine, its salts, isomers, and salts of its isomers;
2 (4) Methylphenidate; and
3 (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.
4 (d) Any material, compound, mixture, or preparation which contains
5 any quantity of the following substances having a potential for abuse
6 associated with a depressant effect on the central nervous system,
7 including their salts, isomers, and salts of isomers whenever the
8 existence of such salts, isomers, and salts of isomers is possible within
9 the specific chemical designations:
10 (1) Amobarbital;
11 (2) Secobarbital;
12 (3) Pentobarbital;
13 (4) Phencyclidine; and
14 (5) Glutethimide.
15 (e) Hallucinogenic substances known as:
16 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-
17 dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-
18 dibenzo(b,d)pyran-9-one; and
19 (2) Dronabinol in an oral solution in a drug product approved by the
20 federal Food and Drug Administration.
21 (f) Unless specifically excepted or unless listed in another
22 schedule, any material, compound, mixture, or preparation which contains
23 any quantity of the following substances:
24 (1) Immediate precursor to amphetamine and methamphetamine:
25 Phenylacetone. Trade and other names shall include, but are not limited
26 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl
27 ketone;
28 (2) Immediate precursors to phencyclidine, PCP:
29 (A) 1-phenylcyclohexylamine; or
30 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or
31 (3) Immediate precursor to fentanyl; 4-anilino-N-phenethylpiperidine
-33-
LB230 LB230
2025 2025
1 (ANPP); or .
2 (4) Tianeptine, its salts, isomers, and salts of isomers whenever
3 the existence of such salts, isomers, and salts of isomers is possible
4 within the specific chemical designation.
5 Schedule III
6 (a) Any material, compound, mixture, or preparation which contains
7 any quantity of the following substances having a potential for abuse
8 associated with a stimulant effect on the central nervous system,
9 including their salts, isomers, whether optical, position, or geometric,
10 and salts of such isomers whenever the existence of such salts, isomers,
11 and salts of isomers is possible within the specific chemical
12 designation:
13 (1) Benzphetamine;
14 (2) Chlorphentermine;
15 (3) Clortermine; and
16 (4) Phendimetrazine.
17 (b) Any material, compound, mixture, or preparation which contains
18 any quantity of the following substances having a potential for abuse
19 associated with a depressant effect on the central nervous system:
20 (1) Any substance which contains any quantity of a derivative of
21 barbituric acid or any salt of a derivative of barbituric acid, except
22 those substances which are specifically listed in other schedules of this
23 section;
24 (2) Aprobarbital;
25 (3) Butabarbital;
26 (4) Butalbital;
27 (5) Butethal;
28 (6) Butobarbital;
29 (7) Chlorhexadol;
30 (8) Embutramide;
31 (9) Lysergic acid;
-34-
LB230 LB230
2025 2025
1 (10) Lysergic acid amide;
2 (11) Methyprylon;
3 (12) Perampanel;
4 (13) Secbutabarbital;
5 (14) Sulfondiethylmethane;
6 (15) Sulfonethylmethane;
7 (16) Sulfonmethane;
8 (17) Nalorphine;
9 (18) Talbutal;
10 (19) Thiamylal;
11 (20) Thiopental;
12 (21) Vinbarbital;
13 (22) Any compound, mixture, or preparation containing amobarbital,
14 secobarbital, pentobarbital, or any salt thereof and one or more other
15 active medicinal ingredients which are not listed in any schedule;
16 (23) Any suppository dosage form containing amobarbital,
17 secobarbital, pentobarbital, or any salt of any of these drugs and
18 approved by the federal Food and Drug Administration for marketing only
19 as a suppository;
20 (24) Any drug product containing gamma-hydroxybutyric acid,
21 including its salts, isomers, and salts of isomers, for which an
22 application is approved under section 505 of the Federal Food, Drug, and
23 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;
24 (25) Ketamine, its salts, isomers, and salts of isomers. Some other
25 names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-
26 cyclohexanone; and
27 (26) Tiletamine and zolazepam or any salt thereof. Trade or other
28 names for a tiletamine-zolazepam combination product shall include, but
29 are not limited to: telazol. Trade or other names for tiletamine shall
30 include, but are not limited to: 2-(ethylamino)-2-(2-thienyl)-
31 cyclohexanone. Trade or other names for zolazepam shall include, but are
-35-
LB230 LB230
2025 2025
1 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
2 trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrazapon.
3 (c) Unless specifically excepted or unless listed in another
4 schedule:
5 (1) Any material, compound, mixture, or preparation containing
6 limited quantities of any of the following narcotic drugs, or any salts
7 calculated as the free anhydrous base or alkaloid, in limited quantities
8 as set forth below:
9 (A) Not more than one and eight-tenths grams of codeine per one
10 hundred milliliters or not more than ninety milligrams per dosage unit,
11 with an equal or greater quantity of an isoquinoline alkaloid of opium;
12 (B) Not more than one and eight-tenths grams of codeine per one
13 hundred milliliters or not more than ninety milligrams per dosage unit,
14 with one or more active, nonnarcotic ingredients in recognized
15 therapeutic amounts;
16 (C) Not more than one and eight-tenths grams of dihydrocodeine per
17 one hundred milliliters or not more than ninety milligrams per dosage
18 unit, with one or more active, nonnarcotic ingredients in recognized
19 therapeutic amounts;
20 (D) Not more than three hundred milligrams of ethylmorphine per one
21 hundred milliliters or not more than fifteen milligrams per dosage unit,
22 with one or more active, nonnarcotic ingredients in recognized
23 therapeutic amounts;
24 (E) Not more than five hundred milligrams of opium per one hundred
25 milliliters or per one hundred grams, or not more than twenty-five
26 milligrams per dosage unit, with one or more active, nonnarcotic
27 ingredients in recognized therapeutic amounts; and
28 (F) Not more than fifty milligrams of morphine per one hundred
29 milliliters or per one hundred grams with one or more active, nonnarcotic
30 ingredients in recognized therapeutic amounts; and
31 (2) Any material, compound, mixture, or preparation containing any
-36-
LB230 LB230
2025 2025
1 of the following narcotic drug or its salts, as set forth below:
2 (A) Buprenorphine.
3 (d) Unless contained on the list of exempt anabolic steroids of the
4 Drug Enforcement Administration of the United States Department of
5 Justice as the list existed on January 31, 2022, any anabolic steroid,
6 which shall include any material, compound, mixture, or preparation
7 containing any quantity of the following substances, including its salts,
8 isomers, and salts of isomers whenever the existence of such salts of
9 isomers is possible within the specific chemical designation:
10 (1) 3-beta,17-dihydroxy-5a-androstane;
11 (2) 3-alpha,17-beta-dihydroxy-5a-androstane;
12 (3) 5-alpha-androstan-3,17-dione;
13 (4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-
14 ene);
15 (5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-
16 ene);
17 (6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
18 (7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
19 (8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);
20 (9) 4-androstenedione (androst-4-en-3,17-dione);
21 (10) 5-androstenedione (androst-5-en-3,17-dione);
22 (11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-
23 hydroxyandrost-4-en-3-one);
24 (12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one);
25 (13) Boldione (androsta-1,4-diene-3,17-3-one);
26 (14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-
27 en-3-one);
28 (15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);
29 (16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-
30 alpha-methyl-androst-1,4-dien-3-one);
31 (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-
-37-
LB230 LB230
2025 2025
1 en-17-beta-ol) (a.k.a. 'madol');
2 (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
3 hydroxy-5-alpha-androst-1-en-3-one);
4 (19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);
5 (20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-
6 androstan-3-one);
7 (21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);
8 (22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta-
9 dihydroxyandrost-4-en-3-one);
10 (23) Formebulone (formebolone); (2-formyl-17-alpha-methyl-11-
11 alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);
12 (24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-
13 furazan);
14 (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;
15 (26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one);
16 (27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-
17 one);
18 (28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
19 one);
20 (29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
21 one);
22 (30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-
23 dien-3-one);
24 (31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-
25 ene);
26 (32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-
27 beta-ol-3-one);
28 (33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-
29 one);
30 (34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;
31 (35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
-38-
LB230 LB230
2025 2025
1 (36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;
2 (37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-
3 hydroxy-17-beta-hydroxyestr-4-en-3-one);
4 (38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-
5 dien-3-one);
6 (39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-
7 trien-3-one);
8 (40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-
9 en-3-one);
10 (41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-
11 en-3-one);
12 (42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-
13 hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha-
14 methyl-1-testosterone');
15 (43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);
16 (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);
17 (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);
18 (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);
19 (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);
20 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-
21 dione);
22 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
23 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
24 (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-
25 en-3-one);
26 (52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);
27 (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-
28 one);
29 (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-
30 one);
31 (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-
-39-
LB230 LB230
2025 2025
1 androstan-3-one);
2 (56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-
3 en-3-one);
4 (57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-
5 hydroxy-[5-alpha]-androstan-3-one);
6 (58) Prostanozol (17-beta-hydroxy-5-alpha-androstano[3,2-
7 c]pyrazole);
8 (59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-
9 androst-2-eno[3,2-c]-pyrazole);
10 (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-
11 one);
12 (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-
13 oic acid lactone);
14 (62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
15 (63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta-
16 hydroxygon-4,9,11-trien-3-one);
17 (64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one);
18 (65) [3,2-c]-furazan-5 alpha-androstane-17 beta-ol;
19 (66) [3,2-c]pyrazole-androst-4-en-17 beta-ol;
20 (67) 17 alpha-methyl-androst-ene-3,17 beta-diol;
21 (68) 17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
22 (69) 17 alpha-methyl-androstan-3-hydroxyimine-17 beta-ol;
23 (70) 17 beta-hydroxy-androstano[2,3-d]isoxazole;
24 (71) 17 beta-hydroxy-androstano[3,2-c]isoxazole;
25 (72) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;
26 (73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17
27 beta-ol;
28 (74) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3-one;
29 (75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-
30 dione;
31 (76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol;
-40-
LB230 LB230
2025 2025
1 (77) 4-chloro-17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
2 (78) 4-hydroxy-androst-4-ene-3,17-dione;
3 (79) 5 alpha-Androstan-3,6,17-trione;
4 (80) 6-bromo-androst-1,4-diene-3,17-dione;
5 (81) 6-bromo-androstan-3,17-dione;
6 (82) 6 alpha-methyl-androst-4-ene-3,17-dione;
7 (83) Delta 1-dihydrotestosterone;
8 (84) Estra-4,9,11-triene-3,17-dione; and
9 (85) Any salt, ester, or ether of a drug or substance described or
10 listed in this subdivision if the salt, ester, or ether promotes muscle
11 growth.
12 (e) Hallucinogenic substances known as:
13 (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft
14 gelatin capsule in a drug product approved by the federal Food and Drug
15 Administration. Some other names for dronabinol are (6aR-
16 trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo
17 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.
18 Schedule IV
19 (a) Any material, compound, mixture, or preparation which contains
20 any quantity of the following substances, including their salts, isomers,
21 and salts of isomers whenever the existence of such salts, isomers, and
22 salts of isomers is possible within the specific chemical designation:
23 (1) Barbital;
24 (2) Chloral betaine;
25 (3) Chloral hydrate;
26 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide
27 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and
28 water soluble esterified estrogens);
29 (5) Clonazepam;
30 (6) Clorazepate;
31 (7) Daridorexant;
-41-
LB230 LB230
2025 2025
1 (8) Diazepam;
2 (9) Ethchlorvynol;
3 (10) Ethinamate;
4 (11) Flurazepam;
5 (12) Mebutamate;
6 (13) Meprobamate;
7 (14) Methohexital;
8 (15) Methylphenobarbital;
9 (16) Oxazepam;
10 (17) Paraldehyde;
11 (18) Petrichloral;
12 (19) Phenobarbital;
13 (20) Prazepam;
14 (21) Alprazolam;
15 (22) Bromazepam;
16 (23) Camazepam;
17 (24) Clobazam;
18 (25) Clotiazepam;
19 (26) Cloxazolam;
20 (27) Delorazepam;
21 (28) Estazolam;
22 (29) Ethyl loflazepate;
23 (30) Fludiazepam;
24 (31) Flunitrazepam;
25 (32) Halazepam;
26 (33) Haloxazolam;
27 (34) Ketazolam;
28 (35) Loprazolam;
29 (36) Lorazepam;
30 (37) Lormetazepam;
31 (38) Medazepam;
-42-
LB230 LB230
2025 2025
1 (39) Nimetazepam;
2 (40) Nitrazepam;
3 (41) Nordiazepam;
4 (42) Oxazolam;
5 (43) Pinazepam;
6 (44) Temazepam;
7 (45) Tetrazepam;
8 (46) Triazolam;
9 (47) Midazolam;
10 (48) Quazepam;
11 (49) Zolpidem;
12 (50) Dichloralphenazone;
13 (51) Zaleplon;
14 (52) Zopiclone;
15 (53) Fospropofol;
16 (54) Alfaxalone;
17 (55) Suvorexant;
18 (56) Carisoprodol;
19 (57) Brexanolone; 3 alpha-hydroxy-5 alpha-pregnan-20-one;
20 (58) Lemborexant;
21 (59) Solriamfetol; 2-amino-3-phenylpropyl carbamate;
22 (60) Remimazolam; and
23 (61) Serdexmethylphenidate.
24 (b) Any material, compound, mixture, or preparation which contains
25 any quantity of the following substance, including its salts, isomers,
26 whether optical, position, or geometric, and salts of such isomers,
27 whenever the existence of such salts, isomers, and salts of isomers is
28 possible: Fenfluramine.
29 (c) Unless specifically excepted or unless listed in another
30 schedule, any material, compound, mixture, or preparation which contains
31 any quantity of the following substances having a stimulant effect on the
-43-
LB230 LB230
2025 2025
1 central nervous system, including their salts, isomers, whether optical,
2 position, or geometric, and salts of such isomers whenever the existence
3 of such salts, isomers, and salts of isomers is possible within the
4 specific chemical designation:
5 (1) Diethylpropion;
6 (2) Phentermine;
7 (3) Pemoline, including organometallic complexes and chelates
8 thereof;
9 (4) Mazindol;
10 (5) Pipradrol;
11 (6) SPA, ((-)-1-dimethylamino-1,2-diphenylethane);
12 (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);
13 (8) Fencamfamin;
14 (9) Fenproporex;
15 (10) Mefenorex;
16 (11) Modafinil; and
17 (12) Sibutramine.
18 (d) Unless specifically excepted or unless listed in another
19 schedule, any material, compound, mixture, or preparation which contains
20 any quantity of the following narcotic drugs, or their salts or isomers
21 calculated as the free anhydrous base or alkaloid, in limited quantities
22 as set forth below:
23 (1) Propoxyphene in manufactured dosage forms;
24 (2) Not more than one milligram of difenoxin and not less than
25 twenty-five micrograms of atropine sulfate per dosage unit; and
26 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its
27 salts, optical and geometric isomers, and salts of these isomers to
28 include: Tramadol.
29 (e) Unless specifically excepted or unless listed in another
30 schedule, any material, compound, mixture, or preparation which contains
31 any quantity of the following substances substance, including their its
-44-
LB230 LB230
2025 2025
1 salts:
2 (1) Pentazocine; and
3 (2) Butorphanol (including its optical isomers).
4 (f) Any material, compound, mixture, or preparation which contains
5 any quantity of the following substance substances, including its salts,
6 isomers, and salts of such isomers, whenever the existence of such salts,
7 isomers, and salts of isomers is possible: Lorcaserin.
8 (g)(1) Unless specifically excepted or unless listed in another
9 schedule, any material, compound, mixture, or preparation which contains
10 any quantity of the following substance, including its salts, optical
11 isomers, and salts of such optical isomers: Ephedrine.
12 (2) The following drug products containing ephedrine, its salts,
13 optical isomers, and salts of such optical isomers, are excepted from
14 subdivision (g)(1) of Schedule IV if they (A) are stored behind a
15 counter, in an area not accessible to customers, or in a locked case so
16 that a customer needs assistance from an employee to access the drug
17 product; (B) are sold by a person, eighteen years of age or older, in the
18 course of his or her employment to a customer eighteen years of age or
19 older with the following restrictions: No customer shall be allowed to
20 purchase, receive, or otherwise acquire more than three and six-tenths
21 grams of ephedrine base during a twenty-four-hour period; no customer
22 shall purchase, receive, or otherwise acquire more than nine grams of
23 ephedrine base during a thirty-day period; and the customer shall display
24 a valid driver's or operator's license, a Nebraska state identification
25 card, a military identification card, an alien registration card, or a
26 passport as proof of identification; (C) are labeled and marketed in a
27 manner consistent with the pertinent OTC Tentative Final or Final
28 Monograph; (D) are manufactured and distributed for legitimate medicinal
29 use in a manner that reduces or eliminates the likelihood of abuse; and
30 (E) are not marketed, advertised, or represented in any manner for the
31 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or
-45-
LB230 LB230
2025 2025
1 high, heightened sexual performance, or increased muscle mass:
2 (i) Primatene Tablets; and
3 (ii) Bronkaid Dual Action Caplets.
4 Schedule V
5 (a) Any compound, mixture, or preparation containing any of the
6 following limited quantities of narcotic drugs or salts calculated as the
7 free anhydrous base or alkaloid, which shall include one or more
8 nonnarcotic active medicinal ingredients in sufficient proportion to
9 confer upon the compound, mixture, or preparation valuable medicinal
10 qualities other than those possessed by the narcotic drug alone:
11 (1) Not more than two hundred milligrams of codeine per one hundred
12 milliliters or per one hundred grams;
13 (2) Not more than one hundred milligrams of dihydrocodeine per one
14 hundred milliliters or per one hundred grams;
15 (3) Not more than one hundred milligrams of ethylmorphine per one
16 hundred milliliters or per one hundred grams;
17 (4) Not more than two and five-tenths milligrams of diphenoxylate
18 and not less than twenty-five micrograms of atropine sulfate per dosage
19 unit;
20 (5) Not more than one hundred milligrams of opium per one hundred
21 milliliters or per one hundred grams; and
22 (6) Not more than five-tenths milligram of difenoxin and not less
23 than twenty-five micrograms of atropine sulfate per dosage unit.
24 (b) Unless specifically exempted or excluded or unless listed in
25 another schedule, any material, compound, mixture, or preparation which
26 contains any quantity of the following substances having a stimulant
27 effect on the central nervous system, including its salts, isomers, and
28 salts of isomers: Pyrovalerone.
29 (c) Unless specifically exempted or excluded or unless listed in
30 another schedule, any material, compound, mixture, or preparation which
31 contains any quantity of the following substances having a depressant
-46-
LB230 LB230
2025 2025
1 effect on the central nervous system, including its salts, isomers, and
2 salts of isomers:
3 (1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic
4 acid ethyl ester);
5 (2) Ganaxolone;
6 (3) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);
7 (4) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid);
8 (5) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]
9 butanamide) (also referred to as BRV; UCB-34714; Briviact), including its
10 salts;
11 (6) Cenobamate; and
12 (7) Lasmiditan.
13 Sec. 18. Section 77-5601, Revised Statutes Cumulative Supplement,
14 2024, is amended to read:
15 77-5601 (1) From August 1, 2004, through October 31, 2004, there
16 shall be conducted a tax amnesty program with regard to taxes due and
17 owing that have not been reported to the Department of Revenue. Any
18 person applying for tax amnesty shall pay all unreported taxes that were
19 due on or before April 1, 2004. Any person that applies for tax amnesty
20 and is accepted by the Tax Commissioner shall have any penalties and
21 interest waived on unreported and delinquent taxes notwithstanding any
22 other provisions of law to the contrary.
23 (2) To be eligible for the tax amnesty provided by this section, the
24 person shall apply for amnesty within the amnesty period, file a return
25 for each taxable period for which the amnesty is requested by December
26 31, 2004, if no return has been filed, and pay in full all taxes for
27 which amnesty is sought with the return or within thirty days after the
28 application if a return was filed prior to the amnesty period. Tax
29 amnesty shall not be available for any person that is under civil or
30 criminal audit, investigation, or prosecution for unreported or
31 delinquent taxes by this state or the United States Government on or
-47-
LB230 LB230
2025 2025
1 before April 16, 2004.
2 (3) The department shall not seek civil or criminal prosecution
3 against any person for any taxable period for which amnesty has been
4 granted. The Tax Commissioner shall develop forms for applying for the
5 tax amnesty program, develop procedures for qualification for tax
6 amnesty, and conduct a public awareness campaign publicizing the program.
7 (4) If a person elects to participate in the amnesty program, the
8 election shall constitute an express and irrevocable relinquishment of
9 all administrative and judicial rights to challenge the imposition of the
10 tax or its amount. Nothing in this section shall prohibit the department
11 from adjusting a return as a result of any state or federal audit.
12 (5)(a) Except for any local option sales tax collected and returned
13 to the appropriate municipality and any motor vehicle fuel, diesel fuel,
14 and compressed fuel taxes, which shall be deposited in the Highway Trust
15 Fund or Highway Allocation Fund as provided by law, no less than eighty
16 percent of all revenue received pursuant to the tax amnesty program shall
17 be deposited in the General Fund and ten percent, not to exceed five
18 hundred thousand dollars, shall be deposited in the Department of Revenue
19 Enforcement Fund. Any amount that would otherwise be deposited in the
20 Department of Revenue Enforcement Fund that is in excess of the five-
21 hundred-thousand-dollar limitation shall be deposited in the General
22 Fund.
23 (b) For fiscal year 2005-06, all proceeds in the Department of
24 Revenue Enforcement Fund shall be appropriated to the department for
25 purposes of employing investigators, agents, and auditors and otherwise
26 increasing personnel for enforcement of the Nebraska Revenue Act of 1967.
27 (c) For fiscal years after fiscal year 2005-06, twenty percent of
28 all proceeds received during the previous calendar year due to the
29 efforts of auditors and investigators hired pursuant to subdivision (5)
30 (b) of this section, not to exceed seven hundred fifty thousand dollars,
31 shall be deposited in the Department of Revenue Enforcement Fund for
-48-
LB230 LB230
2025 2025
1 purposes of employing investigators and auditors or continuing such
2 employment for purposes of increasing enforcement of the act.
3 (d) Ten percent of all proceeds received during each calendar year
4 due to the contracts entered into pursuant to section 77-367 shall be
5 deposited in the Department of Revenue Enforcement Fund for purposes of
6 identifying nonfilers of returns, underreporters, nonpayers of taxes, and
7 improper or fraudulent payments.
8 (6)(a) The department shall prepare a report by April 1, 2005, and
9 by February 1 of each year thereafter detailing the results of the tax
10 amnesty program and the subsequent enforcement efforts. For the report
11 due April 1, 2005, the report shall include (i) the amount of revenue
12 obtained as a result of the tax amnesty program broken down by tax
13 program, (ii) the amount obtained from instate taxpayers and from out-of-
14 state taxpayers, and (iii) the amount obtained from individual taxpayers
15 and from business enterprises.
16 (b) For reports due in subsequent years, the report shall include
17 (i) the number of personnel hired for purposes of subdivision (5)(b) of
18 this section and their duties, (ii) a description of lists, software,
19 programming, computer equipment, and other technological methods acquired
20 and the purposes of each, and (iii) the amount of new revenue obtained as
21 a result of the new personnel and acquisitions during the prior calendar
22 year, broken down into the same categories as described in subdivision
23 (6)(a) of this section.
24 (7) The Department of Revenue Enforcement Fund is created. Transfers
25 may be made from the Department of Revenue Enforcement Fund to the
26 General Fund at the direction of the Legislature. The Department of
27 Revenue Enforcement Fund may receive transfers from the Civic and
28 Community Center Financing Fund at the direction of the Legislature for
29 the purpose of administering the Sports Arena Facility Financing
30 Assistance Act. The Department of Revenue Enforcement Fund shall include
31 any money credited to the fund (a) under section 77-2703, and such money
-49-
LB230 LB230
2025 2025
1 shall be used by the Department of Revenue to defray the costs incurred
2 to implement Laws 2019, LB237, (b) under the Mechanical Amusement Device
3 Tax Act, and such money shall be used by the department to defray the
4 costs incurred to implement and enforce Laws 2019, LB538, and any rules
5 and regulations adopted and promulgated to carry out Laws 2019, LB538,
6 (c) under section 77-2906, and such money shall be used by the Department
7 of Revenue to defray the costs incurred to implement Laws 2020, LB310,
8 (d) under the Kratom Consumer Protection Act, and such money shall be
9 used by the Department of Revenue to defray the costs incurred to
10 administer the act, and (e) (d) under section 77-3,124. Any money in the
11 Department of Revenue Enforcement Fund available for investment shall be
12 invested by the state investment officer pursuant to the Nebraska Capital
13 Expansion Act and the Nebraska State Funds Investment Act. Beginning
14 October 1, 2024, any investment earnings from investment of money in the
15 fund shall be credited to the General Fund.
16 (8) For purposes of this section, taxes mean any taxes collected by
17 the department, including, but not limited to state and local sales and
18 use taxes, individual and corporate income taxes, financial institutions
19 deposit taxes, motor vehicle fuel, diesel fuel, and compressed fuel
20 taxes, cigarette taxes, transfer taxes, and charitable gaming taxes.
21 Sec. 19. Sections 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
22 15, 17, 18, and 20 of this act become operative on July 1, 2025. Section
23 16 of this act becomes operative three calendar months after the
24 adjournment of this legislative session. The other sections of this act
25 become operative on their effective date.
26 Sec. 20. Original sections 28-405 and 77-5601, Revised Statutes
27 Cumulative Supplement, 2024, are repealed.
28 Sec. 21. Since an emergency exists, this act takes effect when
29 passed and approved according to law.
-50-
[DELETED: yHA B F A A r t p h a w t as2s o n o p t p p t cp o t s o c s u tU C S A t p f t u o tD o R E F f t K CPs0B0L52]
[DELETED: ScS(((a e c p t i f t t p a a wd o a b f p s t a p c bm0(1(2p i b n l t a c p i t3n4( K e m t m o b e o5k6c d o a o s a b f o s7r8(9t0(1( D n c a s k a o2s3c4(5f6t7( D n i a k p i a f t i8c9(0o1o a m p p l o d0L52]
[DELETED: k(( S m a a o a d t hb c i f o i p b d c p ob c i b n l t fr t y o e t rt t f p t s a h oeS 3  ( N p s s o f s p o0d1(2a k p s i a a s t e3c4S5s6N7c8S9c0(1m2o3(4h5f6S7c i t S o N s h a l o e r8p t c a c p t f9i0(1u t y o a w a p o w a0L52]
[DELETED: b( A h c p s b c p t ut(( T f s " s h n be b t F a D A T p i ni(( D f u t i a r a o t0k1( C d o t l f p f s a2c3f4(5b6(7a8(9( A l o k a m a 70h a o i i t p i1q2S3a p t r k p T T C s4d a i d f s p w d i o o5b6( B o t i d d b t T7C8( N p m m p l o d 9k0p1( A f p r s b s o 0L52]
[DELETED: f(o( A p p o c f t p a ci(((k0h1a c o t k p f a i2l S l s o a m a I3O f S a I E4C ( 1 a f t a c5l f a a b t i a s t t6I L A C M R7A8( A v g m p c i b a9a t c b i c w 2 C0P1(2f F a D A f a f w k3p4( A c o r s b v f o c5y6( T d m c a f f p r7a a m a s f a T f s b8r a s n e a r o n c t9a0s1E0L52]
[DELETED: (k d f b i p s o o f s i d c p o v s b i i a sr( I a a i i o d t dsri n c o s w t d a td0(1t2(3h4( A p o r i n p f s5p m d m a6r7k8d b t T C p t s ( o t9s0b1a2S3C p t s ( o s 7 o t a t4d5i6S 9  ( N p s s o f s p o7d8(9( I c a k a o m i 70h1u0L52]
[DELETED: ( T k p i c w a d ns t c a p o o d ni i b n l t a s l a c( U r o e t s a p m b aa k p t d m r t pst t o t p b a l o t dc0S1t K C P A i t r t t2a3a p b t d t a t p o k4p5( F t f v t d s i a c6p o u t o t d F t s v t7d8F9i0t t d a i t v i a p t1d s p t s o a k p o s2p3(4o5v6( N d t a v h o s b m7u n h b g a a h h b h b t T8C9p0(1C0L52]
[DELETED: t t r r i g f u t r o piS 1  ( A p o r a b a n odo(o(0o t T C d i w m e a b1p2r t a o a o o e o t p o3r4T5t6( D t h t T C o t T7C d s n b b b t t r o8e9t0T1(2s m a f d o f d a n t3p4( I i i d t a p i a5m f a i c i a a u6t7o a c o r f a p o t m8a9( A p o r m a t d o t T0C a t a s b i a w t1A0L52]
[DELETED: SK C P A p t t C P Aac t a f a p r o a u t KCCScm0t c o r f i k p a a m1t2( I a m f s i m i a p o a3a4s5t6r7m8S 1  E a o p i t K C9P A n p s s i a0r1s2i3S 1  T d m a a p r a4r5S6(7(8( H t t o s o a f i b n9l t a f c d a b h o0s1d0L52]
[DELETED: ( T i m a h t t o s o a fi b n l t a f c d ab( R w t m s o a pahs p h t t o s o a f i b nl t a f c d a b h os0( N o p m a c c o t1c2( A b e o c s n s i b3d s o f s g f o d t a4c5p6e7n8( H b d o o r u f h9c0(1p2(3( I p a p o t c o t o a d4c5(6f7(8t9(0(1(0L52]
[DELETED: o( A n o p o f n o ptssf( A c c t k t n op o f n o p f a b e oc t i i v o s ( o t s i0g1(2s3T P A a s b s t a r o p4a5(6(7p8e s a t i l i t s i t p a f9o0a1( A g e w i a i t c o t2e3S 1 S 2 R S C S4252 T f a t s o c s6r7c o t l o e p o t D E8A o t U S D o J a t l9e0S1(0L52]
[DELETED: e s a s o i e a e us e w t e o s i ee(((k((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(0L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7( A N8p p 19p0(1(2p3i4( 1 ( i o5i6( P 1 i7o8( A N9p0i1( A N0L52]
[DELETED: p i o i s a so( B Ni( B Np i o i s a so( B ( n Np i o a0g1( 3 N2p i o a g i3s4( N5(6( T N7p8( P N9p i o i s a s o0i1( U 32m3(4(5(6( A 3 4 c7b8(9(0(1(0L52]
[DELETED: ((((((y((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9( B ( n 1 e0p1( F s t i e e0L52]
[DELETED: s a s o i e a e U se l i a s o s n i ts t i a s t i s r tf(m(a(0a1( R o t a r w a a m2w3(4( A o t f o d t s i5a s o i u s e w t6e7t8(9(0(1(2(3(4(5(6(7(8(9(0(1(0L52]
[DELETED: (((((((((0(1a q o t f h s t s2i3e4t5o6( B T a o n s i b a n7l t 3 38d N 59d0( 4 T a o n s1i b a n l t 42m3(4a n l t 4 a5p6( 4 T a o n s7i b a n l t 48m9( P T a o n s0i b a n l t 11a0L52]
[DELETED: ( I T a o n s i b a nl t 7m ( a ( i a Ti((((( P P s m a p o t p p0c1o2e3o4(5(6(7e8e o c s o s s d a9t i w s c s a p0a1a t o i e d i a d p2a b t f F a D A D 6 c o3t4o5o t s i n i s c o6t s s b i r o t n7d8i9F0(1(0L52]
[DELETED: (i2(( P T a o n s i b a nl t 3d(i b a n l t N (0p N1c2( P a o p T a o n3s i b a n l t 14p5(6M a 3 i7a8(9(0(1( S d o S A S d o2S A i a p o t p p c3b a S d w g o n t s4t a e f a p o s p a e c5m d m o p o s p i6s7w8p9(0q1( t ( o t s i t s i0L52]
[DELETED: su s e e i t s Sn o t s p c i nio c o t s s b i u tspm o s t o a t t s cp0( T M t n1c2s3r e o c s a s s4d a t i w s c s a5p a s a t f D 1 c o t6t a t o i D 6 c o t7t8t9i0F1( N A c c a 32n3i r b a a h a h b4c c 2 g5c 1 16p 1 o7t8o9( N A c c a 1 H0y1o0L52]
[DELETED: c c 2 gc 1 1p 1 oto( N A c c a 3np r b a a h a h bc c 2 g0c 1 11p 1 o2t3o4( N A c c 5n6i r b a a h a h b7c c 2 g8c 1 19p 1 o0t1o2( P A c c a 33p s w s a t n a o4t i r b a a h a h b5c c 2 g6c 1 17p 1 o8t9o0( C A c c a 21h0L52]
[DELETED: t p r b a a h a h bc c 2 gc 1 1p 1 ott( B A c c a 3sa h a h b c0c1p 1 12m o t g w o n3f s i o o a o t l r s t a4e5(6s7a h c a h b8c c 1920m o t g w o n1f s i o o a o t l r s t a2e3( T A c c a 34t s w s a t5n a o t i r b a a h c6a h b c c 17m 2 18p 1 o9t0o1( I c A c c a 10L52]
[DELETED: c s w s a t n a o ti r b a a h c a hb c c 1p 2 1p 1 ota a m b p a 1ps0t a 1 p a b o1p2( I c A c c a 13c s w s a t n a o t4i r b a a h c a h5b c c 16p 2 17p 1 o8t9a a m b p a 10p1s2t a 1 p a b o3p4( A n o s c c5m o p n s l e i t6s7F a D A c o c a c8r9( Z 10y i i i e e s1a0L52]
[DELETED: i e e a s i p w t sc(q o a s p a l i s (ta s o s n i t s t is d f p b s o tp r w a f m r f f r o f t r b s w t a g b0s1o2s f a c o t f t o3t r s w o n t c i f4m5( S o t p r b a h h a6t7p8a9a0(1a2(3a4(5a6(7o8(920(1a0L52]
[DELETED: ( 2 w i ak( 2 w ia( 2 w ia( 2 w i a ka(0k1( 1 w i a2k3(4k5(6k7( 28m9N0( 21m2N3( N4w i a k a M o 35m6( 27m w i a k a 2 o829( 20w1( 2 [0L52]
[DELETED: y( 2y( N tb w i a k a 2N( 1w i a k a b o bd0(1i2(3(4(5a6( 6 w i a7k8( 2 w i a k a 2 59d0(1( 2 w i a2k3(4(546(7( 3 w i a k a8M9( 3 w i a k0a1(0L52]
[DELETED: ( n 4 wi(qi a s o s n i t s t is d f 2 w i akwi0a t a p w a a g o w o n f1s o t i r t a e w a a a2h3( 5 w i a k a 54D5(6D7(8H9( 4 w i a k a 40H1(253(4D5( 5 w i a k a 56M7(8D9(0( A s c a q o t f1m0L52]
[DELETED: ((((((( B o b ob(0a1b t i s d b a m f 22a3n o t r s w o n t c i4f5( S i t r s t a e w a6a a h h o h s7w o n f s i t r s b o o m8o9( S a t 3 w a a a0s1( S a t 2 n a w a o2d3s4( U s e o u l i a5s6a7t8i w t e o s s i a s o9i0( A 71y a i i s i a s o0L52]
[DELETED: i(((h 4 4 A SO( U s e o u l i asa0c n s i i s i a s o1i2(3(4( A a 2 o 45d6( C 2 a7a8(9i S o n 2 a0( 2 a1N m m2e3( ( a (4p5( N N6a7(8( 4 ( n 4 49m0( N - p1i i i s i a s o0L52]
[DELETED: i( A c s a t t e i fhS( A o t f s e t n dl i o s w p d o i bec s o b c o e a cs0( O a o a a s c d o1p o o o o e a b2t b d n n3n4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(0L52]
[DELETED: (cts((o c l a a s c d o pts0a s o o i e t t s s n1i d c l o e w d n c2c3(4e l s o p f w c t p5a6(7o8a9s0c1(2(3(4(5(6(7(8(9(0(1( M 40L52]
[DELETED: b( M 2d((((( P ec0( P 11c2(3(4(5(6(7(8(9(0( L w i a k a l1a2(3(4(5(6(7a q o t f s h a p f a8a9( A i s o i a s o i0o1(0L52]
[DELETED: ((((a q o t f s h a p f aa w a d e o t c n si t s i a s o i w tet0(1(2(3(4(5(6( N A n f n (7d 68d9(0f1( U s e o u l i a2s3a4( I p t a a m5P6t P P b m k a m b7k8(9(0(1(0L52]
[DELETED: (( T i s i a s o i wtwS(a q o t f s h a p f aa w a s e o t c n si0a1a s o i i p w t s c2d3(4(5(6(7(8a q o t f s h a p f a9a0( A s w c a q o a d o1b2t3s4(5(6(7(8(9(0(1(0L52]
[DELETED: (((((((((0(1(2(3( A c m o p c a4s5a6( A s d f c a7s p o a s o a o t d a8a9a0( A d p c g a1i i s i a s o i f w a2a3C4(5n f k (6c7( T a z o a s t T o o8n9a0i b a n l t 21c0L52]
[DELETED: n l t 4t( U s e o u l i as( A m c m o p clca( N m t o a e g o c p o0h1w2( N m t o a e g o c p o3h4w o o m a n i i r5t6(7o h m o n m t n m p d8u w o o m a n i i r9t0(1h2w o o m a n i i r3t4(5m o p o h g o n m t t6m p d u w o o m a n7i8( N m t f m o m p o h9m0i1(0L52]
[DELETED: o((D E A o t U S D oJw s i a m c m o pci a s o i w t e o s s oi0(1(2(3( 1 (4e5( 1 (6e7(8(9(0(1(2( B (3h4(5(6(7e8(9( D (0a1( D (0L52]
[DELETED: e( D ( 'h(( D (a(( F (d0( F ( (1a2( F (3f4(5(6( 4 (7o8( M (9o0( M (1o2( M (3d4(5e6( M (7b8( M (9o0(1(0L52]
[DELETED: (( 1 (h( M (d( M (t( M (e0( M (1e2( 1 (3h ( '4m5(6(7(8(9(0( 1 (1d2(3(4( N ( 15e6(7( N (8o9( N (0o1( O (0L52]
[DELETED: a( O (e( O (h( P (c( S (a0( S (1o2( T (3o4(5( T ( 16h7(8(9(0(1(2(3(4(5(6( 2 a 3 a a a7b8(9( 4 a b0d1(0L52]
[DELETED: (((((((((0l1g2(3(4g5A S o n f d a (6t7(8S9(0a1a2s3(4(5(6( C b n i l (7h a c b o m ( a8w9(0(1(0L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(0L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5a q o t f s i i s i6w o p o g a s o s i7w8p9( U s e o u l i a0s1a0L52]
[DELETED: cpo s s i a s o i i p w ts((( P i o c a ct(0(1(2(3(4(5(6(7(8( U s e o u l i a9s0a1c2a3(4( N m t o m o d a n l t5t6( 2 i7s o a g i a s o t i t8i9( U s e o u l i a0s1a0L52]
[DELETED: s(((aii( U s e o u l i as0a q o t f s i i s o1i2( T f d p c e i s3o i a s o s o i a e f4s ( o S I i t ( a s b 5c6t a c n a f a e t a t d7p8c9o0p r o o a m t t a s1g o e b d a t p n c2s p r o o a m t n g o3e4a5c6p7m c w t p O T F o F8M9u0(1i0L52]
[DELETED: h((S( A c m o p c a o tff a b o a w s i o o mn a m i i s p tc u t c m o p v m0q1(2m3(4h5( N m t o h m o e p o6h7( N m t t a f m o d8a9u0(1m2( N m t f m o d a n l3t4( U s e o e o u l i5a6c a q o t f s h a s7e8s9( U s e o e o u l i0a1c a q o t f s h a d0L52]
[DELETED: es( E (a(((( B (b0s1(2(3S 1 S 7 R S C S4257 ( F A 1 2 t O 3 2 t6s b c a t a p w r t t d a7o t h n b r t t D o R A8p9d0a i a b t T C s h a p a1i w o u a d t n a2o3(4p5f63 2 i n r h b f a p i f a t f7w8a i a r w f p t t a p T9a s n b a f a p t i u c o0c a i o p f u o1d t b t s o t U S G o o0L52]
[DELETED: b( T d s n s c o c pa a p f a t p f w a h bgt a p d p f q f ta(e s c a e a i r oa0t1f2(3t4a5F6p7b d i t G F a t p n t e f8h9E F A a t w o b d i t0D o R E F t i i e o t f1h l s b d i t G2F3( F f y 2 a p i t D o4R E F s b a t t d f5p6i7( F f y a f y 2 t p o8a p r d t p c y d t t9e0(1s b d i t D o R E F f0L52]
[DELETED: p o e i a a o c se(d t t c e i p t s 7 s bdii(b0a p a t s e e F t r1d A 1 2 t r s i ( t a o r2o a a r o t t a p b d b t3p4s5a6( F r d i s y t r s i7(8t s a t d ( a d o l s9p0a1a2y3(4(5m b m f t D o R E F t t6G F a t d o t L T D o7R E F m r t f t C a8C9t p o a t S A F F0A1a0L52]
[DELETED: stTca(o( u t K C P A a s m s bu b t D o R t d t c i t0a1D2i3E A a t N S F I A B4O5f6(7t8u9d t m v f d f a c f0t1S2131 o t a b o t c m a t4a5b6S 2  O s 2 a 7 R S7C8S 2  S a e e t a t e w9p0L52]


================================================================================

Raw Text:
LB230 LB230
2025 2025
LEGISLATURE OF NEBRASKA
ONE HUNDRED NINTH LEGISLATURE
FIRST SESSION
LEGISLATIVE BILL 230
FINAL READING
Introduced by Hallstrom, 1.
Read first time January 14, 2025
Committee: Judiciary
1 A BILL FOR AN ACT relating to public health and welfare; to amend
2 sections 28-405 and 77-5601, Revised Statutes Cumulative Supplement,
3 2024; to adopt the Kratom Consumer Protection Act; to regulate the
4 sale of nitrous oxide products; to provide penalties; to change
5 provisions of the schedules of controlled substances under the
6 Uniform Controlled Substances Act; to provide for the use of the
7 Department of Revenue Enforcement Fund for the Kratom Consumer
8 Protection Act; to provide operative dates; to repeal the original
9 sections; and to declare an emergency.
10 Be it enacted by the people of the State of Nebraska,
-1-

LB230 LB230
2025 2025
1 Section 1. Sections 1 to 15 of this act shall be known and may be
2 cited as the Kratom Consumer Protection Act.
3 Sec. 2. For purposes of the Kratom Consumer Protection Act:
4 (1) Attractive to children means products:
5 (a) Manufactured in the shape of humans, cartoons, or animals; or
6 (b) Manufactured in a form that bears any reasonable resemblance to
7 an existing candy product that is familiar to the public as a widely
8 distributed or a branded food product such that a product could be
9 mistaken for the branded food product, especially by children;
10 (2) Department means the Department of Revenue;
11 (3) Kratom means the plant mitragyna speciosa or any part of that
12 plant, including, but not limited to, all components present in the
13 natural plant;
14 (4) Kratom extract means the material obtained by extraction of
15 kratom leaves with a solvent consisting of water, ethanol, or food-grade
16 carbon dioxide, or any other solvent allowed by federal or state
17 regulation to be used in manufacturing a food ingredient;
18 (5) Kratom product means a food, ingredient, or dietary supplement
19 that:
20 (a) Consists of or contains kratom or kratom extract;
21 (b) Does not contain any synthesized kratom alkaloids, other
22 synthesized kratom constituents, or synthesized metabolites of any kratom
23 constituent;
24 (c) Does not contain a level of 7-hydroxymitragynine in the alkaloid
25 fraction that is greater than two percent of the alkaloid composition of
26 the kratom product; and
27 (d) Does not include any kratom product in any form that is
28 combustible, is intended to be used for vaporization, or is injectable;
29 (6) Processor means a person that manufacturers, packages, labels,
30 or distributes kratom products or advertises, represents, or holds itself
31 out as manufacturing, preparing, packaging, labeling, or distributing
-2-

LB230 LB230
2025 2025
1 kratom products;
2 (7) Retailer has the same meaning as in section 77-2701.32; and
3 (8) Synthesized means an alkaloid or alkaloid derivative that has
4 been created, in full or in part, by directed chemical, physical, or
5 biosynthetic conversion, including, but not limited to, fermentation,
6 recombinant techniques, yeast-derived, or enzymatic techniques, rather
7 than traditional food preparation techniques, such as heating or
8 extracting.
9 Sec. 3. (1) No person shall sell, offer for sale, provide, or
10 distribute a kratom product to a person under twenty-one years of age.
11 (2) An online retailer or marketplace that sells or offers for sale
12 a kratom product shall implement an age-verification system to ensure
13 compliance with this section.
14 Sec. 4. No person shall produce, manufacture, distribute, offer for
15 sale, sell, or introduce into commerce a kratom product in the State of
16 Nebraska if the product is manufactured in a manner that is attractive to
17 children.
18 Sec. 5. A kratom product sold, offered for sale, or introduced into
19 commerce in the State of Nebraska shall:
20 (1) Be manufactured, packaged, labeled, or held in a facility that
21 meets the requirements of 21 C.F.R. Part 111, as such regulations existed
22 on January 1, 2025; and
23 (2) Be manufactured, processed, packed, or held by a processor who
24 has registered with the federal Food and Drug Administration as a food
25 facility.
26 Sec. 6. A kratom product sold, offered for sale, or introduced into
27 commerce in the State of Nebraska shall have a label on each retail
28 package that clearly and conspicuously provides the following
29 information:
30 (1) The product is not recommended for use by individuals who are
31 under twenty-one years of age, who are pregnant, or who are
-3-

LB230 LB230
2025 2025
1 breastfeeding;
2 (2) A health care practitioner should be consulted prior to using
3 the product;
4 (3) The product may be habit-forming;
5 (4) The following statements: "These statements have not been
6 evaluated by the Food and Drug Administration. This product is not
7 intended to diagnose, treat, cure, or prevent any disease.";
8 (5) The name and place of business of the processor;
9 (6) Directions for use that include a recommended amount of the
10 kratom product per serving that is:
11 (a) Clearly described on the label for product forms such as
12 capsules, gummies, prepackaged, single-serving units, and similar product
13 forms; or
14 (b) A clear instruction or a mark on the package or container for
15 beverages or liquids;
16 (7) A recommended number of servings that can be safely consumed in
17 a twenty-four-hour period;
18 (8) A listing of the servings per container; and
19 (9) A listing of kratom alkaloids mitragynine and 7-
20 hydroxymitragynine and other ingredients in the product, including
21 quantitative declarations of the amount per serving of mitragynine.
22 Sec. 7. (1) The department shall establish, operate, and administer
23 a program to register kratom products. The Tax Commissioner shall
24 designate an implementation date for such program which date is on or
25 before January 1, 2026.
26 (2) Beginning on the implementation date designated by the Tax
27 Commissioner pursuant to subsection (1) of this section:
28 (a) No processor may manufacture, package, label, or distribute a
29 kratom product to be offered for sale in the State of Nebraska unless the
30 product has been registered with the department;
31 (b) Applications for product registration shall be submitted on a
-4-

LB230 LB230
2025 2025
1 form prescribed by the department. Each application shall include:
2 (i) The name, address, and state of organization for the processor
3 of the product;
4 (ii) A principal point of contact for the processor and contact
5 information for the point of contact;
6 (iii) The name of the product;
7 (iv) The product label;
8 (v) A certificate of analysis for the kratom product that states the
9 kratom product's alkaloid content and certifies that the kratom product
10 has a level of 7-hydroxymitragynine that is less than two percent of the
11 alkaloid composition of the kratom product from an independent
12 laboratory. Such laboratory shall obtain and maintain an International
13 Organization for Standardization and International Electrotechnical
14 Commission (ISO/IEC) 17025 accreditation for testing and calibration
15 laboratories from an accreditation body that is a signatory to the
16 International Laboratory Accreditation Cooperation Mutual Recognition
17 Arrangement;
18 (vi) A valid good manufacturing practice certificate issued by an
19 accredited third-party certification body in compliance with 21 C.F.R.
20 Part 111; and
21 (vii) A current food facility registration certificate issued by the
22 federal Food and Drug Administration for all facilities where kratom
23 products are manufactured, prepared, packaged, or labeled;
24 (c) A certificate of registration shall be valid for one calendar
25 year after the date of issue and shall not be transferable;
26 (d) The department may charge a fee for product registration
27 applications and may adjust such fee annually. The fee shall be
28 reasonable and shall not exceed any reasonable or necessary costs to
29 administer the Kratom Consumer Protection Act. The department shall remit
30 such fees to the State Treasurer for credit to the Department of Revenue
31 Enforcement Fund; and
-5-

LB230 LB230
2025 2025
1 (e) A product that contains the same kratom ingredients in the same
2 kratom delivery form, but is packaged, sold, or offered for sale in a
3 different container, package, or volume shall be included in a single
4 registration.
5 (3) If an application is incomplete or deficient, the department
6 shall, in a timely manner, notify the applicant in writing describing the
7 reason or reasons and request additional information. If such application
8 is not corrected or supplemented within thirty days after the
9 department's request, the department shall deny the application.
10 (4) If any false statement is made in any part of an application,
11 the department shall deny the application.
12 (5) A person aggrieved by the denial of an application may request a
13 hearing pursuant to section 11 of this act.
14 (6) A processor or retailer is not prohibited from selling,
15 preparing, manufacturing, distributing, maintaining, advertising,
16 representing, or holding itself out as selling, preparing, or maintaining
17 kratom products in the State of Nebraska prior to the implementation date
18 designated by the Tax Commissioner pursuant to subsection (1) of this
19 section, or while the first product registration applications submitted
20 by processors operating in the State of Nebraska as of January 1, 2025,
21 are pending approval or denial by the department.
22 Sec. 8. Beginning on the implementation date designated by the Tax
23 Commissioner pursuant to subsection (1) of section 7 of this act, the
24 department shall make public a list of all registered kratom products on
25 its website.
26 Sec. 9. (1) No person shall sell, offer for sale, provide, or
27 distribute an adulterated kratom product in the State of Nebraska.
28 (2) A product shall be deemed adulterated if:
29 (a) It contains any kratom alkaloid or metabolite, including 7-
30 hydroxymitragynine, and does not meet the definition of a kratom product
31 under section 2 of this act; or
-6-

LB230 LB230
2025 2025
1 (b) The kratom product is combined with a dangerous nonkratom
2 substance that contains a poisonous or otherwise deleterious nonkratom
3 ingredient, including, but not limited to, any substance listed as a
4 controlled substance under the laws of this state or federal law.
5 (3) Upon receipt of evidence that suggests a product may be an
6 adulterated kratom product, the department may require the person
7 selling, providing, or distributing the product to obtain an independent
8 third-party test of the product by a laboratory of the department's
9 choosing.
10 Sec. 10. (1) Any processor or retailer that violates any section of
11 the Kratom Consumer Protection Act, including those related to the
12 application or registration, or any of the rules and regulations adopted
13 and promulgated by the department that apply to processors or kratom
14 products shall be subject to the penalties provided in this section.
15 (2) For the first violation, the department shall impose a civil
16 penalty of up to one thousand dollars. For the second violation, the
17 department shall impose a civil penalty of up to five thousand dollars.
18 For a third violation and any subsequent violations, the department shall
19 impose a civil penalty of at least five thousand dollars and no more than
20 twenty thousand dollars and, if the violator is a processor, the
21 department shall prohibit the sale of any kratom products of such
22 processor within the State of Nebraska for a period of three years.
23 (3) For any processor or retailer that has no violation for a period
24 of four consecutive years, a new violation shall be treated as a first
25 violation.
26 (4) No determination that a violation has occurred shall be made
27 until notice has been given and a hearing has been held by the Tax
28 Commissioner as provided in section 11 of this act if requested by the
29 processor or retailer.
30 (5) A retailer shall not be found to be in violation of the Kratom
31 Consumer Protection Act if it is shown by a preponderance of the evidence
-7-

LB230 LB230
2025 2025
1 that the retailer relied in good faith upon the representation of a
2 processor that a product is not an adulterated kratom product as defined
3 in section 9 of this act or otherwise conformed to the act.
4 Sec. 11. (1) A processor or retailer aggrieved by a notice of
5 denial of an application issued under section 7 of this act or a notice
6 of violation issued under section 10 of this act may request a hearing.
7 (2) Such request shall be made within twenty days after the receipt
8 of any such notice.
9 (3) At such hearing the Tax Commissioner, or any officer or employee
10 of the Tax Commissioner designated in writing, may examine any books,
11 papers, memoranda, or other evidence bearing upon the matter at issue and
12 require the attendance of any officer or employee of the processor or
13 retailer or any person having knowledge pertinent to such hearing. The
14 Tax Commissioner or the Tax Commissioner's designee may administer oaths
15 to persons testifying at such hearing.
16 (4) During the hearing, the Tax Commissioner or the Tax
17 Commissioner's designee shall not be bound by the technical rules of
18 evidence, and no informality in any proceeding or in the manner of taking
19 testimony shall invalidate any order or decision made or approved by the
20 Tax Commissioner.
21 (5) Within a reasonable time after the hearing the Tax Commissioner
22 shall make a final decision or final determination and notify the
23 processor or retailer by mail of such decision or determination.
24 (6) If it is determined that a processor intentionally and
25 materially falsified any information contained in an application under
26 the Kratom Consumer Protection Act, the processor shall be ineligible to
27 obtain a certification of registration for a period of twelve months
28 after the date of such determination.
29 (7) A processor or retailer may appeal the decision of the Tax
30 Commissioner, and the appeal shall be in accordance with the
31 Administrative Procedure Act.
-8-

LB230 LB230
2025 2025
1 Sec. 12. The Attorney General shall have authority to enforce the
2 Kratom Consumer Protection Act pursuant to the Consumer Protection Act
3 and the Uniform Deceptive Trade Practices Act. This section shall not be
4 construed to allow for a private right of action under the Kratom
5 Consumer Protection Act even though such action is authorized under the
6 Consumer Protection Act and the Uniform Deceptive Trade Practices Act.
7 Sec. 13. (1) If a registered processor has been convicted by any
8 court of a violation of the Kratom Consumer Protection Act, the processor
9 may, in addition to the penalties for such offense, incur a forfeiture of
10 the certificate of registration for its kratom products and all money
11 that had been paid for such certificate of registration.
12 (2) If any materially false statement is made in any part of an
13 application submitted under section 7 of this act, the applicant shall be
14 subject to prosecution for perjury and if convicted may, in addition to
15 the penalties for such offense, incur a forfeiture of any certificate of
16 registration that was issued for the applicant's kratom products and all
17 money that had been paid for such certificate of registration.
18 Sec. 14. Except as otherwise provided in the Kratom Consumer
19 Protection Act, no political subdivision shall impose additional
20 restrictions on the manufacturing, packaging, labeling, distribution, or
21 sale of kratom products greater than or in addition to those enumerated
22 in the act.
23 Sec. 15. The department may adopt and promulgate rules and
24 regulations to carry out the Kratom Consumer Protection Act.
25 Sec. 16. (1) For purposes of this section:
26 (a) Delivery sale has the same meaning as in section 28-1418.01;
27 (b) Flavored nitrous oxide product means a nitrous oxide product:
28 (i) Having the taste or smell of any food, including, but not
29 limited to, any fruit, candy, dessert, alcoholic beverage, herb, or
30 spice, that is distinguishable by an ordinary consumer either prior to or
31 during consumption or use of the product;
-9-

LB230 LB230
2025 2025
1 (ii) That is marketed as having the taste or smell of any food,
2 including, but not limited to, any fruit, candy, dessert, alcoholic
3 beverage, herb, or spice; or
4 (iii) Regarding which the manufacturer, seller, or any person
5 authorized by, or acting with the consent of, the manufacturer or seller,
6 has made a public statement or claim, whether express or implied, that
7 such product has the taste or smell of any food, including, but not
8 limited to, any fruit, candy, dessert, alcoholic beverage, herb, or
9 spice; and
10 (c) Nitrous oxide product means a cartridge, cylinder, or tank
11 containing nitrous oxide.
12 (2) A business entity or corporation shall not sell, including by
13 delivery sale, offer for sale, give, furnish, or distribute to any
14 consumer in this state a nitrous oxide product or flavored nitrous oxide
15 product or willingly allow such products to be taken from such business
16 entity or corporation by any person. This subsection does not apply to a
17 nitrous oxide product, other than a flavored nitrous oxide product, that:
18 (a) Has been denatured or otherwise rendered unfit for human
19 consumption for use;
20 (b) Is intended for use by a manufacturer as part of a manufacturing
21 process or industrial operation;
22 (c) Is intended for use for automotive purposes;
23 (d) Is prescribed as part of the care or treatment of a disease,
24 condition, or injury by a licensed medical or dental practitioner; or
25 (e) Is a propellant in food or in food preparation for restaurant,
26 food service, or houseware products.
27 (3) A business entity or corporation that violates subsection (2) of
28 this section shall be subject to:
29 (a) A Class II misdemeanor for a first offense;
30 (b) A Class I misdemeanor for a second or subsequent offense; and
31 (c) A civil penalty of two thousand five hundred dollars for a first
-10-

LB230 LB230
2025 2025
1 or a subsequent offense.
2 (4) All nitrous oxide products or flavored nitrous oxide products
3 that are sold, offered for sale, given, or furnished in violation of this
4 section are subject to seizure, forfeiture, and destruction. The cost of
5 such seizure, forfeiture, and destruction shall be borne by the person
6 from whom the products are seized.
7 (5) Any common carrier that knowingly transports nitrous oxide
8 products or flavored nitrous oxide products for a business entity or
9 corporation that is in violation of subsection (2) of this section is
10 guilty of a Class II misdemeanor.
11 (6) In addition to any other penalty, a violation of this section
12 shall constitute a deceptive trade practice under the Uniform Deceptive
13 Trade Practices Act and shall be subject to any remedies or penalties
14 available for a violation of such act.
15 (7) This section does not apply to the following:
16 (a) The shipment of nitrous oxide products or flavored nitrous oxide
17 products to a foreign-trade zone that is established under 19 U.S.C. 81a
18 et seq., and that is located in this state if the products are from
19 outside of this country, were ordered by a distributor in another state,
20 and are not distributed in this state; or
21 (b) A government employee who is acting in the course of the
22 employee's official duties.
23 Sec. 17. Section 28-405, Revised Statutes Cumulative Supplement,
24 2024, is amended to read:
25 28-405 The following are the schedules of controlled substances
26 referred to in the Uniform Controlled Substances Act, unless specifically
27 contained on the list of exempted products of the Drug Enforcement
28 Administration of the United States Department of Justice as the list
29 existed on January 31, 2022:
30 Schedule I
31 (a) Any of the following opiates, including their isomers, esters,
-11-

LB230 LB230
2025 2025
1 ethers, salts, and salts of isomers, esters, and ethers, unless
2 specifically excepted, whenever the existence of such isomers, esters,
3 ethers, and salts is possible within the specific chemical designation:
4 (1) Acetylmethadol;
5 (2) Allylprodine;
6 (3) Alphacetylmethadol, except levo-alphacetylmethadol which is also
7 known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
8 (4) Alphameprodine;
9 (5) Alphamethadol;
10 (6) Benzethidine;
11 (7) Betacetylmethadol;
12 (8) Betameprodine;
13 (9) Betamethadol;
14 (10) Betaprodine;
15 (11) Clonitazene;
16 (12) Dextromoramide;
17 (13) Difenoxin;
18 (14) Diampromide;
19 (15) Diethylthiambutene;
20 (16) Dimenoxadol;
21 (17) Dimepheptanol;
22 (18) Dimethylthiambutene;
23 (19) Dioxaphetyl butyrate;
24 (20) Dipipanone;
25 (21) Ethylmethylthiambutene;
26 (22) Etonitazene;
27 (23) Etoxeridine;
28 (24) Furethidine;
29 (25) Hydroxypethidine;
30 (26) Ketobemidone;
31 (27) Levomoramide;
-12-

LB230 LB230
2025 2025
1 (28) Levophenacylmorphan;
2 (29) Morpheridine;
3 (30) Noracymethadol;
4 (31) Norlevorphanol;
5 (32) Normethadone;
6 (33) Norpipanone;
7 (34) Phenadoxone;
8 (35) Phenampromide;
9 (36) Phenomorphan;
10 (37) Phenoperidine;
11 (38) Piritramide;
12 (39) Proheptazine;
13 (40) Properidine;
14 (41) Propiram;
15 (42) Racemoramide;
16 (43) Trimeperidine;
17 (44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-
18 piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
19 piperidine;
20 (45) Tilidine;
21 (46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
22 phenylpropanamide, its optical and geometric isomers, salts, and salts of
23 isomers;
24 (47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical
25 isomers, salts, and salts of isomers;
26 (48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its
27 optical isomers, salts, and salts of isomers;
28 (49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-
29 piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of
30 isomers;
31 (50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-
-13-

LB230 LB230
2025 2025
1 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
2 of isomers;
3 (51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide,
4 its optical isomers, salts, and salts of isomers;
5 (52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-
6 piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts
7 of isomers;
8 (53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-
9 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and
10 geometric isomers, salts, and salts of isomers;
11 (54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-
12 piperidinyl)-N-phenylpropanamide, its optical and geometric isomers,
13 salts, and salts of isomers;
14 (55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
15 (thenylfentanyl), its optical isomers, salts, and salts of isomers;
16 (56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-
17 propanamide, its optical isomers, salts, and salts of isomers;
18 (57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-
19 piperidinyl)propanamide, its optical isomers, salts, and salts of
20 isomers;
21 (58) U-47700, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
22 methylbenzamide;
23 (59) 4-Fluoroisobutyryl Fentanyl;
24 (60) Acetyl Fentanyl;
25 (61) Acyrloylfentanyl;
26 (62) AH-7921; 3, 4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]
27 benzamide;
28 (63) Butyryl fentanyl;
29 (64) Cyclopentyl fentanyl;
30 (65) Cyclopropyl fentanyl;
31 (66) Furanyl fentanyl;
-14-

LB230 LB230
2025 2025
1 (67) Isobutyryl fentanyl;
2 (68) Isotonitazene;
3 (69) Methoxyacetyl fentanyl;
4 (70) MT-45; 1-cyclohexyl-4-(1,2-diphenylethyl) piperazine;
5 (71) Tetrahydrofuranyl fentanyl;
6 (72) 2-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-
7 yl) propionamide;
8 (73) Ocfentanil;
9 (74) Ortho-Fluorofentanyl;
10 (75) Para-chloroisobutyryl fentanyl;
11 (76) Para-Fluorobutyryl Fentanyl;
12 (77) Valeryl fentanyl;
13 (78) Phenyl Fentanyl;
14 (79) Para-Methylfentanyl;
15 (80) Thiofuranyl Fentanyl;
16 (81) Beta-methyl Fentanyl;
17 (82) Beta'-Phenyl Fentanyl;
18 (83) Crotonyl Fentanyl;
19 (84) 2'-Fluoro Ortho-Fluorofentanyl;
20 (85) 4'-Methyl Acetyl Fentanyl;
21 (86) Ortho-Fluorobutyryl Fentanyl;
22 (87) Ortho-Methyl Acetylfentanyl;
23 (88) Ortho-Methyl Methoxyacetyl Fentanyl;
24 (89) Ortho-Fluoroacryl Fentanyl;
25 (90) Fentanyl Carbamate;
26 (91) Ortho-Fluoroisobutyryl Fentanyl;
27 (92) Para-Fluoro Furanyl Fentanyl;
28 (93) Para-Methoxybutyryl Fentanyl;
29 (94) Brorphine (other name: 1-(1-(1-(4-bromophenyl) ethyl)
30 piperidin-4-yl-1,3-dihydro-2H-benzo[D]imidazole-2-one); and
31 (95) Fentanyl-related substances, their isomers, esters, ethers,
-15-

LB230 LB230
2025 2025
1 salts and salts of isomers, esters, and ethers. Unless specifically
2 excepted, listed in another schedule, or specifically named in this
3 schedule, this includes any substance that is structurally related to
4 fentanyl by one or more of the following modifications:
5 (A) Replacement of the phenyl portion of the phenethyl group by any
6 monocycle, whether or not further substituted in or on the monocycle;
7 (B) Substitution in or on the phenethyl group with alkyl, alkenyl,
8 alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;
9 (C) Substitution in or on the piperidine ring with alkyl, alkenyl,
10 alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups;
11 (D) Replacement of the aniline ring with any aromatic monocycle
12 whether or not further substituted in or on the aromatic monocycle; or
13 (E) Replacement of the N-propionyl group by another acyl group.
14 (b) Any of the following opium derivatives, their salts, isomers,
15 and salts of isomers, unless specifically excepted, whenever the
16 existence of such salts, isomers, and salts of isomers is possible within
17 the specific chemical designation:
18 (1) Acetorphine;
19 (2) Acetyldihydrocodeine;
20 (3) Benzylmorphine;
21 (4) Codeine methylbromide;
22 (5) Codeine-N-Oxide;
23 (6) Cyprenorphine;
24 (7) Desomorphine;
25 (8) Dihydromorphine;
26 (9) Drotebanol;
27 (10) Etorphine, except hydrochloride salt;
28 (11) Heroin;
29 (12) Hydromorphinol;
30 (13) Methyldesorphine;
31 (14) Methyldihydromorphine;
-16-

LB230 LB230
2025 2025
1 (15) Morphine methylbromide;
2 (16) Morphine methylsulfonate;
3 (17) Morphine-N-Oxide;
4 (18) Myrophine;
5 (19) Nicocodeine;
6 (20) Nicomorphine;
7 (21) Normorphine;
8 (22) Pholcodine; and
9 (23) Thebacon.
10 (c) Any material, compound, mixture, or preparation which contains
11 any quantity of the following hallucinogenic substances, their salts,
12 isomers, and salts of isomers, unless specifically excepted, whenever the
13 existence of such salts, isomers, and salts of isomers is possible within
14 the specific chemical designation, and, for purposes of this subdivision
15 only, isomer shall include the optical, position, and geometric isomers:
16 (1) Bufotenine. Trade and other names shall include, but are not
17 limited to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-
18 dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-
19 dimethyltryptamine; and mappine;
20 (2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall
21 include, but are not limited to: 4-bromo-2,5-dimethoxy-alpha-
22 methylphenethylamine; and 4-bromo-2,5-DMA;
23 (3) 4-methoxyamphetamine. Trade and other names shall include, but
24 are not limited to: 4-methoxy-alpha-methylphenethylamine; and
25 paramethoxyamphetamine, PMA;
26 (4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall
27 include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-
28 methylphenethylamine; DOM; and STP;
29 (5) Para-methoxymethamphetamine. Trade and other names shall
30 include, but are not limited to: 1-(4-Methoxyphenyl)-N-methylpropan-2-
31 amine, PMMA, and 4-MMA;
-17-

LB230 LB230
2025 2025
1 (6) Ibogaine. Trade and other names shall include, but are not
2 limited to: 7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-
3 methano-5H-pyrido (1',2':1,2) azepino (5,4-b) indole; and Tabernanthe
4 iboga;
5 (7) Lysergic acid diethylamide;
6 (8) Marijuana;
7 (9) Mescaline;
8 (10) Methoxetamine (MXE);
9 (11) Peyote. Peyote shall mean all parts of the plant presently
10 classified botanically as Lophophora williamsii Lemaire, whether growing
11 or not, the seeds thereof, any extract from any part of such plant, and
12 every compound, manufacture, salts, derivative, mixture, or preparation
13 of such plant or its seeds or extracts;
14 (12) Psilocybin;
15 (13) Psilocyn;
16 (14) Tetrahydrocannabinols, including, but not limited to, synthetic
17 equivalents of the substances contained in the plant or in the resinous
18 extractives of cannabis, sp. or synthetic substances, derivatives, and
19 their isomers with similar chemical structure and pharmacological
20 activity such as the following: Delta 1 cis or trans tetrahydrocannabinol
21 and their optical isomers, excluding dronabinol in a drug product
22 approved by the federal Food and Drug Administration; Delta 6 cis or
23 trans tetrahydrocannabinol and their optical isomers; and Delta 3,4 cis
24 or trans tetrahydrocannabinol and its optical isomers. Since nomenclature
25 of these substances is not internationally standardized, compounds of
26 these structures shall be included regardless of the numerical
27 designation of atomic positions covered. Tetrahydrocannabinols does not
28 include cannabidiol contained in a drug product approved by the federal
29 Food and Drug Administration;
30 (15) N-ethyl-3-piperidyl benzilate;
31 (16) N-methyl-3-piperidyl benzilate;
-18-

LB230 LB230
2025 2025
1 (17) Thiophene analog of phencyclidine. Trade and other names shall
2 include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine;
3 2-thienyl analog of phencyclidine; TPCP; and TCP;
4 (18) Hashish or concentrated cannabis;
5 (19) Parahexyl. Trade and other names shall include, but are not
6 limited to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
7 dibenzo(b,d)pyran; and Synhexyl;
8 (20) Ethylamine analog of phencyclidine. Trade and other names shall
9 include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; (1-
10 phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;
11 cyclohexamine; and PCE;
12 (21) Pyrrolidine analog of phencyclidine. Trade and other names
13 shall include, but are not limited to: 1-(1-phenylcyclohexyl)-
14 pyrrolidine; PCPy; and PHP;
15 (22) Alpha-ethyltryptamine. Some trade or other names: etryptamine;
16 Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole;
17 alpha-ET; and AET;
18 (23) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;
19 (24) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;
20 (25) Alpha-methyltryptamine, which is also known as AMT;
21 (26) Salvia divinorum or Salvinorin A. Salvia divinorum or
22 Salvinorin A includes all parts of the plant presently classified
23 botanically as Salvia divinorum, whether growing or not, the seeds
24 thereof, any extract from any part of such plant, and every compound,
25 manufacture, derivative, mixture, or preparation of such plant, its
26 seeds, or its extracts, including salts, isomers, and salts of isomers
27 whenever the existence of such salts, isomers, and salts of isomers is
28 possible within the specific chemical designation;
29 (27) Any material, compound, mixture, or preparation containing any
30 quantity of synthetically produced cannabinoids as listed in subdivisions
31 (A) through (L) of this subdivision, including their salts, isomers,
-19-

LB230 LB230
2025 2025
1 salts of isomers, and nitrogen, oxygen, or sulfur-heterocyclic analogs,
2 unless specifically excepted elsewhere in this section. Since
3 nomenclature of these synthetically produced cannabinoids is not
4 internationally standardized and may continually evolve, these structures
5 or compounds of these structures shall be included under this
6 subdivision, regardless of their specific numerical designation of atomic
7 positions covered, so long as it can be determined through a recognized
8 method of scientific testing or analysis that the substance contains
9 properties that fit within one or more of the following categories:
10 (A) Tetrahydrocannabinols: Meaning tetrahydrocannabinols naturally
11 contained in a plant of the genus cannabis (cannabis plant), as well as
12 synthetic equivalents of the substances contained in the plant, or in the
13 resinous extractives of cannabis, sp. and/or synthetic substances,
14 derivatives, and their isomers with similar chemical structure and
15 pharmacological activity such as the following: Delta 1 cis or trans
16 tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans
17 tetrahydrocannabinol, and their optical isomers; Delta 3,4 cis or trans
18 tetrahydrocannabinol, and its optical isomers. This subdivision does not
19 include cannabidiol contained in a drug product approved by the federal
20 Food and Drug Administration;
21 (B) Naphthoylindoles: Any compound containing a 3-(1-
22 naphthoyl)indole structure with substitution at the nitrogen atom of the
23 indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
24 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
25 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
26 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
27 tetrahydropyranylmethyl group, whether or not further substituted in or
28 on any of the listed ring systems to any extent;
29 (C) Naphthylmethylindoles: Any compound containing a 1 H-indol-3-
30 yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
31 of the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
-20-

LB230 LB230
2025 2025
1 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
2 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
3 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
4 tetrahydropyranylmethyl group, whether or not further substituted in or
5 on any of the listed ring systems to any extent;
6 (D) Naphthoylpyrroles: Any compound containing a 3-(1-
7 naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
8 pyrrole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
9 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
10 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
11 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
12 tetrahydropyranylmethyl group, whether or not further substituted in or
13 on any of the listed ring systems to any extent;
14 (E) Naphthylideneindenes: Any compound containing a
15 naphthylideneindene structure with substitution at the 3-position of the
16 indene ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
17 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
18 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
19 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
20 tetrahydropyranylmethyl group, whether or not further substituted in or
21 on any of the listed ring systems to any extent;
22 (F) Phenylacetylindoles: Any compound containing a 3-
23 phenylacetylindole structure with substitution at the nitrogen atom of
24 the indole ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
25 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
26 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
27 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
28 tetrahydropyranylmethyl group, whether or not further substituted in or
29 on any of the listed ring systems to any extent;
30 (G) Cyclohexylphenols: Any compound containing a 2-(3-
31 hydroxycyclohexyl)phenol structure with substitution at the 5-position of
-21-

LB230 LB230
2025 2025
1 the phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
2 cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group,
3 cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-
4 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
5 tetrahydropyranylmethyl group, whether or not substituted in or on any of
6 the listed ring systems to any extent;
7 (H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole
8 structure with substitution at the nitrogen atom of the indole ring by an
9 alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
10 cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-
11 piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
12 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
13 further substituted in or on any of the listed ring systems to any
14 extent;
15 (I) Adamantoylindoles: Any compound containing a 3-adamantoylindole
16 structure with substitution at the nitrogen atom of the indole ring by an
17 alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl,
18 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl,
19 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
20 morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
21 further substituted in or on any of the listed ring systems to any
22 extent;
23 (J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-
24 tetramethylcyclopropanoylindole structure with substitution at the
25 nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
26 alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
27 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
28 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
29 tetrahydropyranylmethyl group, whether or not further substituted in or
30 on any of the listed ring systems to any extent;
31 (K) Indole carboxamides: Any compound containing a 1-indole-3-
-22-

LB230 LB230
2025 2025
1 carboxamide structure with substitution at the nitrogen atom of the
2 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
3 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
4 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
5 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
6 tetrahydropyranylmethyl group, substitution at the carboxamide group by
7 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
8 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
9 substituted in or on any of the listed ring systems to any extent or to
10 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
11 propionaldehyde groups to any extent;
12 (L) Indole carboxylates: Any compound containing a 1-indole-3-
13 carboxylate structure with substitution at the nitrogen atom of the
14 indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl,
15 benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
16 piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
17 pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
18 tetrahydropyranylmethyl group, substitution at the carboxylate group by
19 an alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl,
20 phenyl, aminooxoalkyl group, or quinolinyl group, whether or not further
21 substituted in or on any of the listed ring systems to any extent or to
22 the adamantyl, 1-mapthyl, phenyl, aminooxoalkyl, benzyl, or
23 propionaldehyde groups to any extent; and
24 (M) Any nonnaturally occurring substance, chemical compound,
25 mixture, or preparation, not specifically listed elsewhere in these
26 schedules and which is not approved for human consumption by the federal
27 Food and Drug Administration, containing or constituting a cannabinoid
28 receptor agonist as defined in section 28-401;
29 (28) Zipeprol 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-
30 yl]-1-phenylpropan-2-ol, including its isomers, esters, ethers, salts,
31 and salts of isomers, esters, and ethers, whenever the existence of such
-23-

LB230 LB230
2025 2025
1 isomers, esters, ethers, and salts is possible within the specific
2 chemical designation;
3 (29) Any material, compound, mixture, or preparation containing any
4 quantity of a substituted phenethylamine as listed in subdivisions (A)
5 through (C) of this subdivision, unless specifically excepted, listed in
6 another schedule, or specifically named in this schedule, that is
7 structurally derived from phenylethan-2-amine by substitution on the
8 phenyl ring with a fused methylenedioxy ring, fused furan ring, or a
9 fused tetrahydrofuran ring; by substitution with two alkoxy groups; by
10 substitution with one alkoxy and either one fused furan, tetrahydrofuran,
11 or tetrahydropyran ring system; or by substitution with two fused ring
12 systems from any combination of the furan, tetrahydrofuran, or
13 tetrahydropyran ring systems, whether or not the compound is further
14 modified in any of the following ways:
15 (A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,
16 trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-
17 position by any alkyl groups; or (C) substitution at the 2-amino nitrogen
18 atom with alkyl, dialkyl, benzyl, hydroxybenzyl, or methoxybenzyl groups,
19 and including, but not limited to:
20 (i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known
21 as 2C-C or 2,5-Dimethoxy-4-chlorophenethylamine;
22 (ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known
23 as 2C-D or 2,5-Dimethoxy-4-methylphenethylamine;
24 (iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known
25 as 2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;
26 (iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H
27 or 2,5-Dimethoxyphenethylamine;
28 (v) 2-(4-lodo-2,5-dimethoxyphenyl)ethanamine, which is also known as
29 2C-I or 2,5-Dimethoxy-4-iodophenethylamine;
30 (vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known
31 as 2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;
-24-

LB230 LB230
2025 2025
1 (vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also
2 known as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;
3 (viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is
4 also known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;
5 (ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is
6 also known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;
7 (x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known
8 as 2C-B or 2,5-Dimethoxy-4-bromophenethylamine;
9 (xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also
10 known as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;
11 (xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also
12 known as DOI or 2,5-Dimethoxy-4-iodoamphetamine;
13 (xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also
14 known as DOB or 2,5-Dimethoxy-4-bromoamphetamine;
15 (xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also
16 known as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
17 (xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
18 methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-
19 NBOMe or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
20 (xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-
21 methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-
22 NBOMe or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
23 (xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine,
24 which is also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-
25 methoxybenzyl)phenethylamine;
26 (xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
27 methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or
28 25C-NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
29 (xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine,
30 which is also known as 2CB-5-hemiFLY;
31 (xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-
-25-

LB230 LB230
2025 2025
1 yl)ethanamine, which is also known as 2C-B-FLY;
2 (xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-
3 yl)ethanamine, which is also known as 2C-B-butterFLY;
4 (xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-
5 b:4,5-b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-
6 NBOMe;
7 (xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine,
8 which is also known as bromo-benzodifuranylisopropylamine or bromo-
9 dragonFLY;
10 (xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which
11 is also known as 2C-INBOH or 25I-NBOH;
12 (xxv) 5-(2-Aminopropyl)benzofuran, which is also known as 5-APB;
13 (xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;
14 (xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known
15 as 5-APDB;
16 (xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also
17 known as 6-APDB;
18 (xxix) 2,5-dimethoxy-amphetamine, which is also known as 2, 5-
19 dimethoxy-a-methylphenethylamine; 2, 5-DMA;
20 (xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;
21 (xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also
22 known as 2C-T-7;
23 (xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;
24 (xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as
25 4-methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP;
26 (xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;
27 (xxxv) 3,4-methylenedioxymethamphetamine, which is also known as
28 MDMA;
29 (xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known
30 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;
31 (xxxvii) 3,4,5-trimethoxy amphetamine; and
-26-

LB230 LB230
2025 2025
1 (xxxviii) n-hydroxy-3, 4-Methylenedioxy-N-Hydroxyamphetamine, which
2 is also known as N-hydroxyMDA;
3 (30) Any material, compound, mixture, or preparation containing any
4 quantity of a substituted tryptamine unless specifically excepted, listed
5 in another schedule, or specifically named in this schedule, that is
6 structurally derived from 2-(1H-indol-3-yl)ethanamine, which is also
7 known as tryptamine, by mono- or di-substitution of the amine nitrogen
8 with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom
9 in a cyclic structure whether or not the compound is further substituted
10 at the alpha position with an alkyl group or whether or not further
11 substituted on the indole ring to any extent with any alkyl, alkoxy,
12 halo, hydroxyl, or acetoxy groups, and including, but not limited to:
13 (A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-
14 DALT;
15 (B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-
16 DMT or OAcetylpsilocin;
17 (C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-
18 HO-MET;
19 (D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-
20 HO-DIPT;
21 (E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as
22 5-MeOMiPT;
23 (F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-
24 DMT;
25 (G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-
26 MeO-DiPT;
27 (H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine,
28 DET; and
29 (I) Dimethyltryptamine, which is also known as DMT; and
30 (31)(A) Any substance containing any quantity of the following
31 materials, compounds, mixtures, or structures:
-27-

LB230 LB230
2025 2025
1 (i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methylone;
2 (ii) 3,4-methylenedioxypyrovalerone, or MDPV;
3 (iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;
4 (iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;
5 (v) Fluoromethcathinone, or FMC;
6 (vi) Naphthylpyrovalerone, or naphyrone; or
7 (vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or
8 butylone; or
9 (B) Unless listed in another schedule, any substance which contains
10 any quantity of any material, compound, mixture, or structure, other than
11 bupropion, that is structurally derived by any means from 2-
12 aminopropan-1-one by substitution at the 1-position with either phenyl,
13 naphthyl, or thiophene ring systems, whether or not the compound is
14 further modified in any of the following ways:
15 (i) Substitution in the ring system to any extent with alkyl,
16 alkoxy, alkylenedioxy, haloalkyl, hydroxyl, or halide substituents,
17 whether or not further substituted in the ring system by one or more
18 other univalent substituents;
19 (ii) Substitution at the 3-position with an acyclic alkyl
20 substituent; or
21 (iii) Substitution at the 2-amino nitrogen atom with alkyl or
22 dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic
23 structure.
24 (d) Unless specifically excepted or unless listed in another
25 schedule, any material, compound, mixture, or preparation which contains
26 any quantity of the following substances having a depressant effect on
27 the central nervous system, including its salts, isomers, and salts of
28 isomers whenever the existence of such salts, isomers, and salts of
29 isomers is possible within the specific chemical designation:
30 (1) Amineptine 7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-
31 yl)amino]heptanoic acid, including its salts, isomers, and salts of
-28-

LB230 LB230
2025 2025
1 isomers;
2 (2) Mecloqualone;
3 (3) Methaqualone; and
4 (4) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-
5 hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium
6 Oxybate; and Sodium Oxybutyrate.
7 (e) Unless specifically excepted or unless listed in another
8 schedule, any material, compound, mixture, or preparation which contains
9 any quantity of the following substances having a stimulant effect on the
10 central nervous system, including its salts, isomers, and salts of
11 isomers:
12 (1) Fenethylline;
13 (2) N-ethylamphetamine;
14 (3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-
15 dihydro-5-phenyl-2-oxazolamine;
16 (4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-
17 aminopropiophenone; 2-aminopropiophenone; and norephedrone;
18 (5) Methcathinone, its salts, optical isomers, and salts of optical
19 isomers. Some other names: 2-(methylamino)-propiophenone; alpha-
20 (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-
21 N-methylaminopropiophenone; methylcathinone; monomethylpropion;
22 ephedrone; N-methylcathinone; AL-464; AL-422; AL-463; UR1432; and 4-MEC;
23 (6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-
24 phenyl-2-oxazolamine;
25 (7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine;
26 and N,N-alpha-trimethylphenethylamine;
27 (8) Benzylpiperazine, 1-benzylpiperazine;
28 (9) 4,4'-dimethylaminorex (other names: 4,4'-DMAR, 4,5-dihydro-4-
29 methyl-5-(4-methylphenyl)-2-oxazolamine); and
30 (10) N-phenyl-N' -(3-(1- phenylpropan-2-yl)-1,2,3-oxadiazol-3-
31 ium-5-yl)carbamimidate), including its salts, isomers, and salts of
-29-

LB230 LB230
2025 2025
1 isomers.
2 (f) Any controlled substance analogue to the extent intended for
3 human consumption.
4 Schedule II
5 (a) Any of the following substances except those narcotic drugs
6 listed in other schedules whether produced directly or indirectly by
7 extraction from substances of vegetable origin, independently by means of
8 chemical synthesis, or by combination of extraction and chemical
9 synthesis:
10 (1) Opium and opiate, and any salt, compound, derivative, or
11 preparation of opium or opiate, excluding apomorphine, buprenorphine,
12 thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene,
13 naloxone, and naltrexone and their salts, but including the following:
14 (A) Raw opium;
15 (B) Opium extracts;
16 (C) Opium fluid;
17 (D) Powdered opium;
18 (E) Granulated opium;
19 (F) Tincture of opium;
20 (G) Codeine;
21 (H) Ethylmorphine;
22 (I) Etorphine hydrochloride;
23 (J) Hydrocodone;
24 (K) Hydromorphone;
25 (L) Metopon;
26 (M) Morphine;
27 (N) Oxycodone;
28 (O) Oxymorphone;
29 (P) Oripavine;
30 (Q) Thebaine; and
31 (R) Dihydroetorphine;
-30-

LB230 LB230
2025 2025
1 (2) Any salt, compound, derivative, or preparation thereof which is
2 chemically equivalent to or identical with any of the substances referred
3 to in subdivision (1) of this subdivision, except that these substances
4 shall not include the isoquinoline alkaloids of opium;
5 (3) Opium poppy and poppy straw;
6 (4) Coca leaves and any salt, compound, derivative, or preparation
7 of coca leaves, and any salt, compound, derivative, or preparation
8 thereof which is chemically equivalent to or identical with any of these
9 substances, including cocaine or ecgonine and its salts, optical isomers,
10 and salts of optical isomers, except that the substances shall not
11 include decocainized coca leaves or extractions which do not contain
12 cocaine or ecgonine; and
13 (5) Concentrate of poppy straw, the crude extract of poppy straw in
14 either liquid, solid, or powder form which contains the phenanthrene
15 alkaloids of the opium poppy.
16 (b) Unless specifically excepted or unless in another schedule any
17 of the following opiates, including their isomers, esters, ethers, salts,
18 and salts of their isomers, esters, and ethers whenever the existence of
19 such isomers, esters, ethers, and salts is possible within the specific
20 chemical designation, dextrorphan excepted:
21 (1) Alphaprodine;
22 (2) Anileridine;
23 (3) Bezitramide;
24 (4) Diphenoxylate;
25 (5) Fentanyl;
26 (6) Isomethadone;
27 (7) Levomethorphan;
28 (8) Levorphanol;
29 (9) Metazocine;
30 (10) Methadone;
31 (11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl
-31-

LB230 LB230
2025 2025
1 butane;
2 (12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-
3 diphenylpropane-carboxylic acid;
4 (13) Norfentanyl (N-phenyl-N-piperidin-4-yl) propionamide;
5 (14) Oliceridine;
6 (15) Pethidine or meperidine;
7 (16) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
8 (17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
9 carboxylate;
10 (18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-
11 carboxylic acid;
12 (19) Phenazocine;
13 (20) Piminodine;
14 (21) Racemethorphan;
15 (22) Racemorphan;
16 (23) Dihydrocodeine;
17 (24) Bulk Propoxyphene in nondosage forms;
18 (25) Sufentanil;
19 (26) Alfentanil;
20 (27) Levo-alphacetylmethadol which is also known as levo-alpha-
21 acetylmethadol, levomethadyl acetate, and LAAM;
22 (28) Carfentanil;
23 (29) Remifentanil;
24 (30) Tapentadol; and
25 (31) Thiafentanil.
26 (c) Any material, compound, mixture, or preparation which contains
27 any quantity of the following substances having a potential for abuse
28 associated with a stimulant effect on the central nervous system:
29 (1) Amphetamine, its salts, optical isomers, and salts of its
30 optical isomers;
31 (2) Phenmetrazine and its salts;
-32-

LB230 LB230
2025 2025
1 (3) Methamphetamine, its salts, isomers, and salts of its isomers;
2 (4) Methylphenidate; and
3 (5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.
4 (d) Any material, compound, mixture, or preparation which contains
5 any quantity of the following substances having a potential for abuse
6 associated with a depressant effect on the central nervous system,
7 including their salts, isomers, and salts of isomers whenever the
8 existence of such salts, isomers, and salts of isomers is possible within
9 the specific chemical designations:
10 (1) Amobarbital;
11 (2) Secobarbital;
12 (3) Pentobarbital;
13 (4) Phencyclidine; and
14 (5) Glutethimide.
15 (e) Hallucinogenic substances known as:
16 (1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-
17 dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-
18 dibenzo(b,d)pyran-9-one; and
19 (2) Dronabinol in an oral solution in a drug product approved by the
20 federal Food and Drug Administration.
21 (f) Unless specifically excepted or unless listed in another
22 schedule, any material, compound, mixture, or preparation which contains
23 any quantity of the following substances:
24 (1) Immediate precursor to amphetamine and methamphetamine:
25 Phenylacetone. Trade and other names shall include, but are not limited
26 to: Phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl
27 ketone;
28 (2) Immediate precursors to phencyclidine, PCP:
29 (A) 1-phenylcyclohexylamine; or
30 (B) 1-piperidinocyclohexanecarbonitrile, PCC; or
31 (3) Immediate precursor to fentanyl; 4-anilino-N-phenethylpiperidine
-33-

LB230 LB230
2025 2025
1 (ANPP); or .
2 (4) Tianeptine, its salts, isomers, and salts of isomers whenever
3 the existence of such salts, isomers, and salts of isomers is possible
4 within the specific chemical designation.
5 Schedule III
6 (a) Any material, compound, mixture, or preparation which contains
7 any quantity of the following substances having a potential for abuse
8 associated with a stimulant effect on the central nervous system,
9 including their salts, isomers, whether optical, position, or geometric,
10 and salts of such isomers whenever the existence of such salts, isomers,
11 and salts of isomers is possible within the specific chemical
12 designation:
13 (1) Benzphetamine;
14 (2) Chlorphentermine;
15 (3) Clortermine; and
16 (4) Phendimetrazine.
17 (b) Any material, compound, mixture, or preparation which contains
18 any quantity of the following substances having a potential for abuse
19 associated with a depressant effect on the central nervous system:
20 (1) Any substance which contains any quantity of a derivative of
21 barbituric acid or any salt of a derivative of barbituric acid, except
22 those substances which are specifically listed in other schedules of this
23 section;
24 (2) Aprobarbital;
25 (3) Butabarbital;
26 (4) Butalbital;
27 (5) Butethal;
28 (6) Butobarbital;
29 (7) Chlorhexadol;
30 (8) Embutramide;
31 (9) Lysergic acid;
-34-

LB230 LB230
2025 2025
1 (10) Lysergic acid amide;
2 (11) Methyprylon;
3 (12) Perampanel;
4 (13) Secbutabarbital;
5 (14) Sulfondiethylmethane;
6 (15) Sulfonethylmethane;
7 (16) Sulfonmethane;
8 (17) Nalorphine;
9 (18) Talbutal;
10 (19) Thiamylal;
11 (20) Thiopental;
12 (21) Vinbarbital;
13 (22) Any compound, mixture, or preparation containing amobarbital,
14 secobarbital, pentobarbital, or any salt thereof and one or more other
15 active medicinal ingredients which are not listed in any schedule;
16 (23) Any suppository dosage form containing amobarbital,
17 secobarbital, pentobarbital, or any salt of any of these drugs and
18 approved by the federal Food and Drug Administration for marketing only
19 as a suppository;
20 (24) Any drug product containing gamma-hydroxybutyric acid,
21 including its salts, isomers, and salts of isomers, for which an
22 application is approved under section 505 of the Federal Food, Drug, and
23 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1, 2014;
24 (25) Ketamine, its salts, isomers, and salts of isomers. Some other
25 names for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-
26 cyclohexanone; and
27 (26) Tiletamine and zolazepam or any salt thereof. Trade or other
28 names for a tiletamine-zolazepam combination product shall include, but
29 are not limited to: telazol. Trade or other names for tiletamine shall
30 include, but are not limited to: 2-(ethylamino)-2-(2-thienyl)-
31 cyclohexanone. Trade or other names for zolazepam shall include, but are
-35-

LB230 LB230
2025 2025
1 not limited to: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-
2 trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-one, and flupyrazapon.
3 (c) Unless specifically excepted or unless listed in another
4 schedule:
5 (1) Any material, compound, mixture, or preparation containing
6 limited quantities of any of the following narcotic drugs, or any salts
7 calculated as the free anhydrous base or alkaloid, in limited quantities
8 as set forth below:
9 (A) Not more than one and eight-tenths grams of codeine per one
10 hundred milliliters or not more than ninety milligrams per dosage unit,
11 with an equal or greater quantity of an isoquinoline alkaloid of opium;
12 (B) Not more than one and eight-tenths grams of codeine per one
13 hundred milliliters or not more than ninety milligrams per dosage unit,
14 with one or more active, nonnarcotic ingredients in recognized
15 therapeutic amounts;
16 (C) Not more than one and eight-tenths grams of dihydrocodeine per
17 one hundred milliliters or not more than ninety milligrams per dosage
18 unit, with one or more active, nonnarcotic ingredients in recognized
19 therapeutic amounts;
20 (D) Not more than three hundred milligrams of ethylmorphine per one
21 hundred milliliters or not more than fifteen milligrams per dosage unit,
22 with one or more active, nonnarcotic ingredients in recognized
23 therapeutic amounts;
24 (E) Not more than five hundred milligrams of opium per one hundred
25 milliliters or per one hundred grams, or not more than twenty-five
26 milligrams per dosage unit, with one or more active, nonnarcotic
27 ingredients in recognized therapeutic amounts; and
28 (F) Not more than fifty milligrams of morphine per one hundred
29 milliliters or per one hundred grams with one or more active, nonnarcotic
30 ingredients in recognized therapeutic amounts; and
31 (2) Any material, compound, mixture, or preparation containing any
-36-

LB230 LB230
2025 2025
1 of the following narcotic drug or its salts, as set forth below:
2 (A) Buprenorphine.
3 (d) Unless contained on the list of exempt anabolic steroids of the
4 Drug Enforcement Administration of the United States Department of
5 Justice as the list existed on January 31, 2022, any anabolic steroid,
6 which shall include any material, compound, mixture, or preparation
7 containing any quantity of the following substances, including its salts,
8 isomers, and salts of isomers whenever the existence of such salts of
9 isomers is possible within the specific chemical designation:
10 (1) 3-beta,17-dihydroxy-5a-androstane;
11 (2) 3-alpha,17-beta-dihydroxy-5a-androstane;
12 (3) 5-alpha-androstan-3,17-dione;
13 (4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-
14 ene);
15 (5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-
16 ene);
17 (6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
18 (7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
19 (8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);
20 (9) 4-androstenedione (androst-4-en-3,17-dione);
21 (10) 5-androstenedione (androst-5-en-3,17-dione);
22 (11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-
23 hydroxyandrost-4-en-3-one);
24 (12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one);
25 (13) Boldione (androsta-1,4-diene-3,17-3-one);
26 (14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-
27 en-3-one);
28 (15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);
29 (16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-
30 alpha-methyl-androst-1,4-dien-3-one);
31 (17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-
-37-

LB230 LB230
2025 2025
1 en-17-beta-ol) (a.k.a. 'madol');
2 (18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
3 hydroxy-5-alpha-androst-1-en-3-one);
4 (19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);
5 (20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-
6 androstan-3-one);
7 (21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);
8 (22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta-
9 dihydroxyandrost-4-en-3-one);
10 (23) Formebulone (formebolone); (2-formyl-17-alpha-methyl-11-
11 alpha,17-beta-dihydroxyandrost-1,4-dien-3-one);
12 (24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-
13 furazan);
14 (25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;
15 (26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one);
16 (27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-
17 one);
18 (28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
19 one);
20 (29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-
21 one);
22 (30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-
23 dien-3-one);
24 (31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-
25 ene);
26 (32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-
27 beta-ol-3-one);
28 (33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-
29 one);
30 (34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;
31 (35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
-38-

LB230 LB230
2025 2025
1 (36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;
2 (37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-
3 hydroxy-17-beta-hydroxyestr-4-en-3-one);
4 (38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-
5 dien-3-one);
6 (39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-
7 trien-3-one);
8 (40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-
9 en-3-one);
10 (41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-
11 en-3-one);
12 (42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-
13 hydroxy-17-alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha-
14 methyl-1-testosterone');
15 (43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);
16 (44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);
17 (45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);
18 (46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);
19 (47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);
20 (48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-
21 dione);
22 (49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
23 (50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
24 (51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-
25 en-3-one);
26 (52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);
27 (53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-
28 one);
29 (54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-
30 one);
31 (55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-
-39-

LB230 LB230
2025 2025
1 androstan-3-one);
2 (56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-
3 en-3-one);
4 (57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-
5 hydroxy-[5-alpha]-androstan-3-one);
6 (58) Prostanozol (17-beta-hydroxy-5-alpha-androstano[3,2-
7 c]pyrazole);
8 (59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-
9 androst-2-eno[3,2-c]-pyrazole);
10 (60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-
11 one);
12 (61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-
13 oic acid lactone);
14 (62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
15 (63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta-
16 hydroxygon-4,9,11-trien-3-one);
17 (64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one);
18 (65) [3,2-c]-furazan-5 alpha-androstane-17 beta-ol;
19 (66) [3,2-c]pyrazole-androst-4-en-17 beta-ol;
20 (67) 17 alpha-methyl-androst-ene-3,17 beta-diol;
21 (68) 17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
22 (69) 17 alpha-methyl-androstan-3-hydroxyimine-17 beta-ol;
23 (70) 17 beta-hydroxy-androstano[2,3-d]isoxazole;
24 (71) 17 beta-hydroxy-androstano[3,2-c]isoxazole;
25 (72) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;
26 (73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17
27 beta-ol;
28 (74) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3-one;
29 (75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-
30 dione;
31 (76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol;
-40-

LB230 LB230
2025 2025
1 (77) 4-chloro-17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
2 (78) 4-hydroxy-androst-4-ene-3,17-dione;
3 (79) 5 alpha-Androstan-3,6,17-trione;
4 (80) 6-bromo-androst-1,4-diene-3,17-dione;
5 (81) 6-bromo-androstan-3,17-dione;
6 (82) 6 alpha-methyl-androst-4-ene-3,17-dione;
7 (83) Delta 1-dihydrotestosterone;
8 (84) Estra-4,9,11-triene-3,17-dione; and
9 (85) Any salt, ester, or ether of a drug or substance described or
10 listed in this subdivision if the salt, ester, or ether promotes muscle
11 growth.
12 (e) Hallucinogenic substances known as:
13 (1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft
14 gelatin capsule in a drug product approved by the federal Food and Drug
15 Administration. Some other names for dronabinol are (6aR-
16 trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo
17 (b,d)pyran-1-ol or (-)-delta-9-(trans)-tetrahydrocannabinol.
18 Schedule IV
19 (a) Any material, compound, mixture, or preparation which contains
20 any quantity of the following substances, including their salts, isomers,
21 and salts of isomers whenever the existence of such salts, isomers, and
22 salts of isomers is possible within the specific chemical designation:
23 (1) Barbital;
24 (2) Chloral betaine;
25 (3) Chloral hydrate;
26 (4) Chlordiazepoxide, but not including librax (chlordiazepoxide
27 hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and
28 water soluble esterified estrogens);
29 (5) Clonazepam;
30 (6) Clorazepate;
31 (7) Daridorexant;
-41-

LB230 LB230
2025 2025
1 (8) Diazepam;
2 (9) Ethchlorvynol;
3 (10) Ethinamate;
4 (11) Flurazepam;
5 (12) Mebutamate;
6 (13) Meprobamate;
7 (14) Methohexital;
8 (15) Methylphenobarbital;
9 (16) Oxazepam;
10 (17) Paraldehyde;
11 (18) Petrichloral;
12 (19) Phenobarbital;
13 (20) Prazepam;
14 (21) Alprazolam;
15 (22) Bromazepam;
16 (23) Camazepam;
17 (24) Clobazam;
18 (25) Clotiazepam;
19 (26) Cloxazolam;
20 (27) Delorazepam;
21 (28) Estazolam;
22 (29) Ethyl loflazepate;
23 (30) Fludiazepam;
24 (31) Flunitrazepam;
25 (32) Halazepam;
26 (33) Haloxazolam;
27 (34) Ketazolam;
28 (35) Loprazolam;
29 (36) Lorazepam;
30 (37) Lormetazepam;
31 (38) Medazepam;
-42-

LB230 LB230
2025 2025
1 (39) Nimetazepam;
2 (40) Nitrazepam;
3 (41) Nordiazepam;
4 (42) Oxazolam;
5 (43) Pinazepam;
6 (44) Temazepam;
7 (45) Tetrazepam;
8 (46) Triazolam;
9 (47) Midazolam;
10 (48) Quazepam;
11 (49) Zolpidem;
12 (50) Dichloralphenazone;
13 (51) Zaleplon;
14 (52) Zopiclone;
15 (53) Fospropofol;
16 (54) Alfaxalone;
17 (55) Suvorexant;
18 (56) Carisoprodol;
19 (57) Brexanolone; 3 alpha-hydroxy-5 alpha-pregnan-20-one;
20 (58) Lemborexant;
21 (59) Solriamfetol; 2-amino-3-phenylpropyl carbamate;
22 (60) Remimazolam; and
23 (61) Serdexmethylphenidate.
24 (b) Any material, compound, mixture, or preparation which contains
25 any quantity of the following substance, including its salts, isomers,
26 whether optical, position, or geometric, and salts of such isomers,
27 whenever the existence of such salts, isomers, and salts of isomers is
28 possible: Fenfluramine.
29 (c) Unless specifically excepted or unless listed in another
30 schedule, any material, compound, mixture, or preparation which contains
31 any quantity of the following substances having a stimulant effect on the
-43-

LB230 LB230
2025 2025
1 central nervous system, including their salts, isomers, whether optical,
2 position, or geometric, and salts of such isomers whenever the existence
3 of such salts, isomers, and salts of isomers is possible within the
4 specific chemical designation:
5 (1) Diethylpropion;
6 (2) Phentermine;
7 (3) Pemoline, including organometallic complexes and chelates
8 thereof;
9 (4) Mazindol;
10 (5) Pipradrol;
11 (6) SPA, ((-)-1-dimethylamino-1,2-diphenylethane);
12 (7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);
13 (8) Fencamfamin;
14 (9) Fenproporex;
15 (10) Mefenorex;
16 (11) Modafinil; and
17 (12) Sibutramine.
18 (d) Unless specifically excepted or unless listed in another
19 schedule, any material, compound, mixture, or preparation which contains
20 any quantity of the following narcotic drugs, or their salts or isomers
21 calculated as the free anhydrous base or alkaloid, in limited quantities
22 as set forth below:
23 (1) Propoxyphene in manufactured dosage forms;
24 (2) Not more than one milligram of difenoxin and not less than
25 twenty-five micrograms of atropine sulfate per dosage unit; and
26 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its
27 salts, optical and geometric isomers, and salts of these isomers to
28 include: Tramadol.
29 (e) Unless specifically excepted or unless listed in another
30 schedule, any material, compound, mixture, or preparation which contains
31 any quantity of the following substances substance, including their its
-44-

LB230 LB230
2025 2025
1 salts:
2 (1) Pentazocine; and
3 (2) Butorphanol (including its optical isomers).
4 (f) Any material, compound, mixture, or preparation which contains
5 any quantity of the following substance substances, including its salts,
6 isomers, and salts of such isomers, whenever the existence of such salts,
7 isomers, and salts of isomers is possible: Lorcaserin.
8 (g)(1) Unless specifically excepted or unless listed in another
9 schedule, any material, compound, mixture, or preparation which contains
10 any quantity of the following substance, including its salts, optical
11 isomers, and salts of such optical isomers: Ephedrine.
12 (2) The following drug products containing ephedrine, its salts,
13 optical isomers, and salts of such optical isomers, are excepted from
14 subdivision (g)(1) of Schedule IV if they (A) are stored behind a
15 counter, in an area not accessible to customers, or in a locked case so
16 that a customer needs assistance from an employee to access the drug
17 product; (B) are sold by a person, eighteen years of age or older, in the
18 course of his or her employment to a customer eighteen years of age or
19 older with the following restrictions: No customer shall be allowed to
20 purchase, receive, or otherwise acquire more than three and six-tenths
21 grams of ephedrine base during a twenty-four-hour period; no customer
22 shall purchase, receive, or otherwise acquire more than nine grams of
23 ephedrine base during a thirty-day period; and the customer shall display
24 a valid driver's or operator's license, a Nebraska state identification
25 card, a military identification card, an alien registration card, or a
26 passport as proof of identification; (C) are labeled and marketed in a
27 manner consistent with the pertinent OTC Tentative Final or Final
28 Monograph; (D) are manufactured and distributed for legitimate medicinal
29 use in a manner that reduces or eliminates the likelihood of abuse; and
30 (E) are not marketed, advertised, or represented in any manner for the
31 indication of stimulation, mental alertness, euphoria, ecstasy, a buzz or
-45-

LB230 LB230
2025 2025
1 high, heightened sexual performance, or increased muscle mass:
2 (i) Primatene Tablets; and
3 (ii) Bronkaid Dual Action Caplets.
4 Schedule V
5 (a) Any compound, mixture, or preparation containing any of the
6 following limited quantities of narcotic drugs or salts calculated as the
7 free anhydrous base or alkaloid, which shall include one or more
8 nonnarcotic active medicinal ingredients in sufficient proportion to
9 confer upon the compound, mixture, or preparation valuable medicinal
10 qualities other than those possessed by the narcotic drug alone:
11 (1) Not more than two hundred milligrams of codeine per one hundred
12 milliliters or per one hundred grams;
13 (2) Not more than one hundred milligrams of dihydrocodeine per one
14 hundred milliliters or per one hundred grams;
15 (3) Not more than one hundred milligrams of ethylmorphine per one
16 hundred milliliters or per one hundred grams;
17 (4) Not more than two and five-tenths milligrams of diphenoxylate
18 and not less than twenty-five micrograms of atropine sulfate per dosage
19 unit;
20 (5) Not more than one hundred milligrams of opium per one hundred
21 milliliters or per one hundred grams; and
22 (6) Not more than five-tenths milligram of difenoxin and not less
23 than twenty-five micrograms of atropine sulfate per dosage unit.
24 (b) Unless specifically exempted or excluded or unless listed in
25 another schedule, any material, compound, mixture, or preparation which
26 contains any quantity of the following substances having a stimulant
27 effect on the central nervous system, including its salts, isomers, and
28 salts of isomers: Pyrovalerone.
29 (c) Unless specifically exempted or excluded or unless listed in
30 another schedule, any material, compound, mixture, or preparation which
31 contains any quantity of the following substances having a depressant
-46-

LB230 LB230
2025 2025
1 effect on the central nervous system, including its salts, isomers, and
2 salts of isomers:
3 (1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic
4 acid ethyl ester);
5 (2) Ganaxolone;
6 (3) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);
7 (4) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid);
8 (5) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]
9 butanamide) (also referred to as BRV; UCB-34714; Briviact), including its
10 salts;
11 (6) Cenobamate; and
12 (7) Lasmiditan.
13 Sec. 18. Section 77-5601, Revised Statutes Cumulative Supplement,
14 2024, is amended to read:
15 77-5601 (1) From August 1, 2004, through October 31, 2004, there
16 shall be conducted a tax amnesty program with regard to taxes due and
17 owing that have not been reported to the Department of Revenue. Any
18 person applying for tax amnesty shall pay all unreported taxes that were
19 due on or before April 1, 2004. Any person that applies for tax amnesty
20 and is accepted by the Tax Commissioner shall have any penalties and
21 interest waived on unreported and delinquent taxes notwithstanding any
22 other provisions of law to the contrary.
23 (2) To be eligible for the tax amnesty provided by this section, the
24 person shall apply for amnesty within the amnesty period, file a return
25 for each taxable period for which the amnesty is requested by December
26 31, 2004, if no return has been filed, and pay in full all taxes for
27 which amnesty is sought with the return or within thirty days after the
28 application if a return was filed prior to the amnesty period. Tax
29 amnesty shall not be available for any person that is under civil or
30 criminal audit, investigation, or prosecution for unreported or
31 delinquent taxes by this state or the United States Government on or
-47-

LB230 LB230
2025 2025
1 before April 16, 2004.
2 (3) The department shall not seek civil or criminal prosecution
3 against any person for any taxable period for which amnesty has been
4 granted. The Tax Commissioner shall develop forms for applying for the
5 tax amnesty program, develop procedures for qualification for tax
6 amnesty, and conduct a public awareness campaign publicizing the program.
7 (4) If a person elects to participate in the amnesty program, the
8 election shall constitute an express and irrevocable relinquishment of
9 all administrative and judicial rights to challenge the imposition of the
10 tax or its amount. Nothing in this section shall prohibit the department
11 from adjusting a return as a result of any state or federal audit.
12 (5)(a) Except for any local option sales tax collected and returned
13 to the appropriate municipality and any motor vehicle fuel, diesel fuel,
14 and compressed fuel taxes, which shall be deposited in the Highway Trust
15 Fund or Highway Allocation Fund as provided by law, no less than eighty
16 percent of all revenue received pursuant to the tax amnesty program shall
17 be deposited in the General Fund and ten percent, not to exceed five
18 hundred thousand dollars, shall be deposited in the Department of Revenue
19 Enforcement Fund. Any amount that would otherwise be deposited in the
20 Department of Revenue Enforcement Fund that is in excess of the five-
21 hundred-thousand-dollar limitation shall be deposited in the General
22 Fund.
23 (b) For fiscal year 2005-06, all proceeds in the Department of
24 Revenue Enforcement Fund shall be appropriated to the department for
25 purposes of employing investigators, agents, and auditors and otherwise
26 increasing personnel for enforcement of the Nebraska Revenue Act of 1967.
27 (c) For fiscal years after fiscal year 2005-06, twenty percent of
28 all proceeds received during the previous calendar year due to the
29 efforts of auditors and investigators hired pursuant to subdivision (5)
30 (b) of this section, not to exceed seven hundred fifty thousand dollars,
31 shall be deposited in the Department of Revenue Enforcement Fund for
-48-

LB230 LB230
2025 2025
1 purposes of employing investigators and auditors or continuing such
2 employment for purposes of increasing enforcement of the act.
3 (d) Ten percent of all proceeds received during each calendar year
4 due to the contracts entered into pursuant to section 77-367 shall be
5 deposited in the Department of Revenue Enforcement Fund for purposes of
6 identifying nonfilers of returns, underreporters, nonpayers of taxes, and
7 improper or fraudulent payments.
8 (6)(a) The department shall prepare a report by April 1, 2005, and
9 by February 1 of each year thereafter detailing the results of the tax
10 amnesty program and the subsequent enforcement efforts. For the report
11 due April 1, 2005, the report shall include (i) the amount of revenue
12 obtained as a result of the tax amnesty program broken down by tax
13 program, (ii) the amount obtained from instate taxpayers and from out-of-
14 state taxpayers, and (iii) the amount obtained from individual taxpayers
15 and from business enterprises.
16 (b) For reports due in subsequent years, the report shall include
17 (i) the number of personnel hired for purposes of subdivision (5)(b) of
18 this section and their duties, (ii) a description of lists, software,
19 programming, computer equipment, and other technological methods acquired
20 and the purposes of each, and (iii) the amount of new revenue obtained as
21 a result of the new personnel and acquisitions during the prior calendar
22 year, broken down into the same categories as described in subdivision
23 (6)(a) of this section.
24 (7) The Department of Revenue Enforcement Fund is created. Transfers
25 may be made from the Department of Revenue Enforcement Fund to the
26 General Fund at the direction of the Legislature. The Department of
27 Revenue Enforcement Fund may receive transfers from the Civic and
28 Community Center Financing Fund at the direction of the Legislature for
29 the purpose of administering the Sports Arena Facility Financing
30 Assistance Act. The Department of Revenue Enforcement Fund shall include
31 any money credited to the fund (a) under section 77-2703, and such money
-49-

LB230 LB230
2025 2025
1 shall be used by the Department of Revenue to defray the costs incurred
2 to implement Laws 2019, LB237, (b) under the Mechanical Amusement Device
3 Tax Act, and such money shall be used by the department to defray the
4 costs incurred to implement and enforce Laws 2019, LB538, and any rules
5 and regulations adopted and promulgated to carry out Laws 2019, LB538,
6 (c) under section 77-2906, and such money shall be used by the Department
7 of Revenue to defray the costs incurred to implement Laws 2020, LB310,
8 (d) under the Kratom Consumer Protection Act, and such money shall be
9 used by the Department of Revenue to defray the costs incurred to
10 administer the act, and (e) (d) under section 77-3,124. Any money in the
11 Department of Revenue Enforcement Fund available for investment shall be
12 invested by the state investment officer pursuant to the Nebraska Capital
13 Expansion Act and the Nebraska State Funds Investment Act. Beginning
14 October 1, 2024, any investment earnings from investment of money in the
15 fund shall be credited to the General Fund.
16 (8) For purposes of this section, taxes mean any taxes collected by
17 the department, including, but not limited to state and local sales and
18 use taxes, individual and corporate income taxes, financial institutions
19 deposit taxes, motor vehicle fuel, diesel fuel, and compressed fuel
20 taxes, cigarette taxes, transfer taxes, and charitable gaming taxes.
21 Sec. 19. Sections 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
22 15, 17, 18, and 20 of this act become operative on July 1, 2025. Section
23 16 of this act becomes operative three calendar months after the
24 adjournment of this legislative session. The other sections of this act
25 become operative on their effective date.
26 Sec. 20. Original sections 28-405 and 77-5601, Revised Statutes
27 Cumulative Supplement, 2024, are repealed.
28 Sec. 21. Since an emergency exists, this act takes effect when
29 passed and approved according to law.
-50-

[DELETED: yHA B F A A r t p h a w t as2s o n o p t p p t cp o t s o c s u tU C S A t p f t u o tD o R E F f t K CPs0B0L52]
[DELETED: ScS(((a e c p t i f t t p a a wd o a b f p s t a p c bm0(1(2p i b n l t a c p i t3n4( K e m t m o b e o5k6c d o a o s a b f o s7r8(9t0(1( D n c a s k a o2s3c4(5f6t7( D n i a k p i a f t i8c9(0o1o a m p p l o d0L52]
[DELETED: k(( S m a a o a d t hb c i f o i p b d c p ob c i b n l t fr t y o e t rt t f p t s a h oeS 3  ( N p s s o f s p o0d1(2a k p s i a a s t e3c4S5s6N7c8S9c0(1m2o3(4h5f6S7c i t S o N s h a l o e r8p t c a c p t f9i0(1u t y o a w a p o w a0L52]
[DELETED: b( A h c p s b c p t ut(( T f s " s h n be b t F a D A T p i ni(( D f u t i a r a o t0k1( C d o t l f p f s a2c3f4(5b6(7a8(9( A l o k a m a 70h a o i i t p i1q2S3a p t r k p T T C s4d a i d f s p w d i o o5b6( B o t i d d b t T7C8( N p m m p l o d 9k0p1( A f p r s b s o 0L52]
[DELETED: f(o( A p p o c f t p a ci(((k0h1a c o t k p f a i2l S l s o a m a I3O f S a I E4C ( 1 a f t a c5l f a a b t i a s t t6I L A C M R7A8( A v g m p c i b a9a t c b i c w 2 C0P1(2f F a D A f a f w k3p4( A c o r s b v f o c5y6( T d m c a f f p r7a a m a s f a T f s b8r a s n e a r o n c t9a0s1E0L52]
[DELETED: (k d f b i p s o o f s i d c p o v s b i i a sr( I a a i i o d t dsri n c o s w t d a td0(1t2(3h4( A p o r i n p f s5p m d m a6r7k8d b t T C p t s ( o t9s0b1a2S3C p t s ( o s 7 o t a t4d5i6S 9  ( N p s s o f s p o7d8(9( I c a k a o m i 70h1u0L52]
[DELETED: ( T k p i c w a d ns t c a p o o d ni i b n l t a s l a c( U r o e t s a p m b aa k p t d m r t pst t o t p b a l o t dc0S1t K C P A i t r t t2a3a p b t d t a t p o k4p5( F t f v t d s i a c6p o u t o t d F t s v t7d8F9i0t t d a i t v i a p t1d s p t s o a k p o s2p3(4o5v6( N d t a v h o s b m7u n h b g a a h h b h b t T8C9p0(1C0L52]
[DELETED: t t r r i g f u t r o piS 1  ( A p o r a b a n odo(o(0o t T C d i w m e a b1p2r t a o a o o e o t p o3r4T5t6( D t h t T C o t T7C d s n b b b t t r o8e9t0T1(2s m a f d o f d a n t3p4( I i i d t a p i a5m f a i c i a a u6t7o a c o r f a p o t m8a9( A p o r m a t d o t T0C a t a s b i a w t1A0L52]
[DELETED: SK C P A p t t C P Aac t a f a p r o a u t KCCScm0t c o r f i k p a a m1t2( I a m f s i m i a p o a3a4s5t6r7m8S 1  E a o p i t K C9P A n p s s i a0r1s2i3S 1  T d m a a p r a4r5S6(7(8( H t t o s o a f i b n9l t a f c d a b h o0s1d0L52]
[DELETED: ( T i m a h t t o s o a fi b n l t a f c d ab( R w t m s o a pahs p h t t o s o a f i b nl t a f c d a b h os0( N o p m a c c o t1c2( A b e o c s n s i b3d s o f s g f o d t a4c5p6e7n8( H b d o o r u f h9c0(1p2(3( I p a p o t c o t o a d4c5(6f7(8t9(0(1(0L52]
[DELETED: o( A n o p o f n o ptssf( A c c t k t n op o f n o p f a b e oc t i i v o s ( o t s i0g1(2s3T P A a s b s t a r o p4a5(6(7p8e s a t i l i t s i t p a f9o0a1( A g e w i a i t c o t2e3S 1 S 2 R S C S4252 T f a t s o c s6r7c o t l o e p o t D E8A o t U S D o J a t l9e0S1(0L52]
[DELETED: e s a s o i e a e us e w t e o s i ee(((k((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(0L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7( A N8p p 19p0(1(2p3i4( 1 ( i o5i6( P 1 i7o8( A N9p0i1( A N0L52]
[DELETED: p i o i s a so( B Ni( B Np i o i s a so( B ( n Np i o a0g1( 3 N2p i o a g i3s4( N5(6( T N7p8( P N9p i o i s a s o0i1( U 32m3(4(5(6( A 3 4 c7b8(9(0(1(0L52]
[DELETED: ((((((y((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9( B ( n 1 e0p1( F s t i e e0L52]
[DELETED: s a s o i e a e U se l i a s o s n i ts t i a s t i s r tf(m(a(0a1( R o t a r w a a m2w3(4( A o t f o d t s i5a s o i u s e w t6e7t8(9(0(1(2(3(4(5(6(7(8(9(0(1(0L52]
[DELETED: (((((((((0(1a q o t f h s t s2i3e4t5o6( B T a o n s i b a n7l t 3 38d N 59d0( 4 T a o n s1i b a n l t 42m3(4a n l t 4 a5p6( 4 T a o n s7i b a n l t 48m9( P T a o n s0i b a n l t 11a0L52]
[DELETED: ( I T a o n s i b a nl t 7m ( a ( i a Ti((((( P P s m a p o t p p0c1o2e3o4(5(6(7e8e o c s o s s d a9t i w s c s a p0a1a t o i e d i a d p2a b t f F a D A D 6 c o3t4o5o t s i n i s c o6t s s b i r o t n7d8i9F0(1(0L52]
[DELETED: (i2(( P T a o n s i b a nl t 3d(i b a n l t N (0p N1c2( P a o p T a o n3s i b a n l t 14p5(6M a 3 i7a8(9(0(1( S d o S A S d o2S A i a p o t p p c3b a S d w g o n t s4t a e f a p o s p a e c5m d m o p o s p i6s7w8p9(0q1( t ( o t s i t s i0L52]
[DELETED: su s e e i t s Sn o t s p c i nio c o t s s b i u tspm o s t o a t t s cp0( T M t n1c2s3r e o c s a s s4d a t i w s c s a5p a s a t f D 1 c o t6t a t o i D 6 c o t7t8t9i0F1( N A c c a 32n3i r b a a h a h b4c c 2 g5c 1 16p 1 o7t8o9( N A c c a 1 H0y1o0L52]
[DELETED: c c 2 gc 1 1p 1 oto( N A c c a 3np r b a a h a h bc c 2 g0c 1 11p 1 o2t3o4( N A c c 5n6i r b a a h a h b7c c 2 g8c 1 19p 1 o0t1o2( P A c c a 33p s w s a t n a o4t i r b a a h a h b5c c 2 g6c 1 17p 1 o8t9o0( C A c c a 21h0L52]
[DELETED: t p r b a a h a h bc c 2 gc 1 1p 1 ott( B A c c a 3sa h a h b c0c1p 1 12m o t g w o n3f s i o o a o t l r s t a4e5(6s7a h c a h b8c c 1920m o t g w o n1f s i o o a o t l r s t a2e3( T A c c a 34t s w s a t5n a o t i r b a a h c6a h b c c 17m 2 18p 1 o9t0o1( I c A c c a 10L52]
[DELETED: c s w s a t n a o ti r b a a h c a hb c c 1p 2 1p 1 ota a m b p a 1ps0t a 1 p a b o1p2( I c A c c a 13c s w s a t n a o t4i r b a a h c a h5b c c 16p 2 17p 1 o8t9a a m b p a 10p1s2t a 1 p a b o3p4( A n o s c c5m o p n s l e i t6s7F a D A c o c a c8r9( Z 10y i i i e e s1a0L52]
[DELETED: i e e a s i p w t sc(q o a s p a l i s (ta s o s n i t s t is d f p b s o tp r w a f m r f f r o f t r b s w t a g b0s1o2s f a c o t f t o3t r s w o n t c i f4m5( S o t p r b a h h a6t7p8a9a0(1a2(3a4(5a6(7o8(920(1a0L52]
[DELETED: ( 2 w i ak( 2 w ia( 2 w ia( 2 w i a ka(0k1( 1 w i a2k3(4k5(6k7( 28m9N0( 21m2N3( N4w i a k a M o 35m6( 27m w i a k a 2 o829( 20w1( 2 [0L52]
[DELETED: y( 2y( N tb w i a k a 2N( 1w i a k a b o bd0(1i2(3(4(5a6( 6 w i a7k8( 2 w i a k a 2 59d0(1( 2 w i a2k3(4(546(7( 3 w i a k a8M9( 3 w i a k0a1(0L52]
[DELETED: ( n 4 wi(qi a s o s n i t s t is d f 2 w i akwi0a t a p w a a g o w o n f1s o t i r t a e w a a a2h3( 5 w i a k a 54D5(6D7(8H9( 4 w i a k a 40H1(253(4D5( 5 w i a k a 56M7(8D9(0( A s c a q o t f1m0L52]
[DELETED: ((((((( B o b ob(0a1b t i s d b a m f 22a3n o t r s w o n t c i4f5( S i t r s t a e w a6a a h h o h s7w o n f s i t r s b o o m8o9( S a t 3 w a a a0s1( S a t 2 n a w a o2d3s4( U s e o u l i a5s6a7t8i w t e o s s i a s o9i0( A 71y a i i s i a s o0L52]
[DELETED: i(((h 4 4 A SO( U s e o u l i asa0c n s i i s i a s o1i2(3(4( A a 2 o 45d6( C 2 a7a8(9i S o n 2 a0( 2 a1N m m2e3( ( a (4p5( N N6a7(8( 4 ( n 4 49m0( N - p1i i i s i a s o0L52]
[DELETED: i( A c s a t t e i fhS( A o t f s e t n dl i o s w p d o i bec s o b c o e a cs0( O a o a a s c d o1p o o o o e a b2t b d n n3n4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(0L52]
[DELETED: (cts((o c l a a s c d o pts0a s o o i e t t s s n1i d c l o e w d n c2c3(4e l s o p f w c t p5a6(7o8a9s0c1(2(3(4(5(6(7(8(9(0(1( M 40L52]
[DELETED: b( M 2d((((( P ec0( P 11c2(3(4(5(6(7(8(9(0( L w i a k a l1a2(3(4(5(6(7a q o t f s h a p f a8a9( A i s o i a s o i0o1(0L52]
[DELETED: ((((a q o t f s h a p f aa w a d e o t c n si t s i a s o i w tet0(1(2(3(4(5(6( N A n f n (7d 68d9(0f1( U s e o u l i a2s3a4( I p t a a m5P6t P P b m k a m b7k8(9(0(1(0L52]
[DELETED: (( T i s i a s o i wtwS(a q o t f s h a p f aa w a s e o t c n si0a1a s o i i p w t s c2d3(4(5(6(7(8a q o t f s h a p f a9a0( A s w c a q o a d o1b2t3s4(5(6(7(8(9(0(1(0L52]
[DELETED: (((((((((0(1(2(3( A c m o p c a4s5a6( A s d f c a7s p o a s o a o t d a8a9a0( A d p c g a1i i s i a s o i f w a2a3C4(5n f k (6c7( T a z o a s t T o o8n9a0i b a n l t 21c0L52]
[DELETED: n l t 4t( U s e o u l i as( A m c m o p clca( N m t o a e g o c p o0h1w2( N m t o a e g o c p o3h4w o o m a n i i r5t6(7o h m o n m t n m p d8u w o o m a n i i r9t0(1h2w o o m a n i i r3t4(5m o p o h g o n m t t6m p d u w o o m a n7i8( N m t f m o m p o h9m0i1(0L52]
[DELETED: o((D E A o t U S D oJw s i a m c m o pci a s o i w t e o s s oi0(1(2(3( 1 (4e5( 1 (6e7(8(9(0(1(2( B (3h4(5(6(7e8(9( D (0a1( D (0L52]
[DELETED: e( D ( 'h(( D (a(( F (d0( F ( (1a2( F (3f4(5(6( 4 (7o8( M (9o0( M (1o2( M (3d4(5e6( M (7b8( M (9o0(1(0L52]
[DELETED: (( 1 (h( M (d( M (t( M (e0( M (1e2( 1 (3h ( '4m5(6(7(8(9(0( 1 (1d2(3(4( N ( 15e6(7( N (8o9( N (0o1( O (0L52]
[DELETED: a( O (e( O (h( P (c( S (a0( S (1o2( T (3o4(5( T ( 16h7(8(9(0(1(2(3(4(5(6( 2 a 3 a a a7b8(9( 4 a b0d1(0L52]
[DELETED: (((((((((0l1g2(3(4g5A S o n f d a (6t7(8S9(0a1a2s3(4(5(6( C b n i l (7h a c b o m ( a8w9(0(1(0L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5(6(7(8(9(0(1(0L52]
[DELETED: (((((((((0(1(2(3(4(5(6(7(8(9(0(1(2(3(4(5a q o t f s i i s i6w o p o g a s o s i7w8p9( U s e o u l i a0s1a0L52]
[DELETED: cpo s s i a s o i i p w ts((( P i o c a ct(0(1(2(3(4(5(6(7(8( U s e o u l i a9s0a1c2a3(4( N m t o m o d a n l t5t6( 2 i7s o a g i a s o t i t8i9( U s e o u l i a0s1a0L52]
[DELETED: s(((aii( U s e o u l i as0a q o t f s i i s o1i2( T f d p c e i s3o i a s o s o i a e f4s ( o S I i t ( a s b 5c6t a c n a f a e t a t d7p8c9o0p r o o a m t t a s1g o e b d a t p n c2s p r o o a m t n g o3e4a5c6p7m c w t p O T F o F8M9u0(1i0L52]
[DELETED: h((S( A c m o p c a o tff a b o a w s i o o mn a m i i s p tc u t c m o p v m0q1(2m3(4h5( N m t o h m o e p o6h7( N m t t a f m o d8a9u0(1m2( N m t f m o d a n l3t4( U s e o e o u l i5a6c a q o t f s h a s7e8s9( U s e o e o u l i0a1c a q o t f s h a d0L52]
[DELETED: es( E (a(((( B (b0s1(2(3S 1 S 7 R S C S4257 ( F A 1 2 t O 3 2 t6s b c a t a p w r t t d a7o t h n b r t t D o R A8p9d0a i a b t T C s h a p a1i w o u a d t n a2o3(4p5f63 2 i n r h b f a p i f a t f7w8a i a r w f p t t a p T9a s n b a f a p t i u c o0c a i o p f u o1d t b t s o t U S G o o0L52]
[DELETED: b( T d s n s c o c pa a p f a t p f w a h bgt a p d p f q f ta(e s c a e a i r oa0t1f2(3t4a5F6p7b d i t G F a t p n t e f8h9E F A a t w o b d i t0D o R E F t i i e o t f1h l s b d i t G2F3( F f y 2 a p i t D o4R E F s b a t t d f5p6i7( F f y a f y 2 t p o8a p r d t p c y d t t9e0(1s b d i t D o R E F f0L52]
[DELETED: p o e i a a o c se(d t t c e i p t s 7 s bdii(b0a p a t s e e F t r1d A 1 2 t r s i ( t a o r2o a a r o t t a p b d b t3p4s5a6( F r d i s y t r s i7(8t s a t d ( a d o l s9p0a1a2y3(4(5m b m f t D o R E F t t6G F a t d o t L T D o7R E F m r t f t C a8C9t p o a t S A F F0A1a0L52]
[DELETED: stTca(o( u t K C P A a s m s bu b t D o R t d t c i t0a1D2i3E A a t N S F I A B4O5f6(7t8u9d t m v f d f a c f0t1S2131 o t a b o t c m a t4a5b6S 2  O s 2 a 7 R S7C8S 2  S a e e t a t e w9p0L52]